CA2251742C - Drug complex - Google Patents

Drug complex Download PDF

Info

Publication number
CA2251742C
CA2251742C CA002251742A CA2251742A CA2251742C CA 2251742 C CA2251742 C CA 2251742C CA 002251742 A CA002251742 A CA 002251742A CA 2251742 A CA2251742 A CA 2251742A CA 2251742 C CA2251742 C CA 2251742C
Authority
CA
Canada
Prior art keywords
group
drug
spacer
paclitaxel
drug complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002251742A
Other languages
French (fr)
Other versions
CA2251742A1 (en
Inventor
Shuichi Sugawara
Masahiro Kajiki
Hiroshi Kuriyama
Nobuya Kitaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Kasei Corp
Original Assignee
Asahi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Corp filed Critical Asahi Kasei Corp
Publication of CA2251742A1 publication Critical patent/CA2251742A1/en
Application granted granted Critical
Publication of CA2251742C publication Critical patent/CA2251742C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Disclosed is a drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, the drug complex being represented by the following formula (1): A-B-C (1) wherein A represents at least one carrier selected from the group consisting of saccharides each having a car- boxyl group, polyethylene glycols each having a carboxyl group, aliphatic carboxylic acids each having a carboxyl group, and derivatives thereof each having a carboxyl group; B represents at least one spacer comprised of a compound having a amino group and a carboxyl group; C represents at least one drug having a hydroxyl group, wherein the carrier A is bonded to the spacer B through an amide bond formed between the carboxyl group of the carrier A and the amino group of the spacer B; and the spacer B is bonded to the drug C through an ester bond formed between the carboxyl group of the spacer B and the hydroxyl group of the drug C. The drug complex of the present invention is capable of not only surely controlling the rate of release of the drug therefrom, but also enhancing the transferability of the drug to target tissues and the pharmacological effect of the drug.

Description

TITLE OF THE INVENTION
Drug complex BACKGROUND OF THE INVENTION
Field of the Invention The present invention relates to a drug complex of a drug having a hydroxyl group, wherein the drug com-plex is capable of controlling the rate of the release of the drug therefrom in blood when administered to a living body. The present invention also relates to a novel polysaccharide-taxane complex which is capable of not only obviating the defect (poor water-solubility) of a drug, for example, a taxane compound which is _ useful as an antitumor drug, but also delaying the disappearance of the taxane compound from blood and also enhancing the transferability of the taxane com-pound to tumor tissues.
n ". ; .",..
Paclitaxel (tradename: Taxol; manufactured and sold by Bristol-Myers Squibb, U.S.A.) is a naturally occurring product, which is extracted from the bark of a taxaceous tree, Taxus brevifolia, native to Pacific-rim countries, and has been confirmed to have excellent antitumor activities by assays using animal models. In recent studies, it has been reported that the antitumor activities of paclitaxel is due to a specific mechanism involving the induction of abnormal polymerization of tubulin and the inhibition of mitosis. Further, in recent years, promising results have been obtained in the studies with respect to the antitumor activities of paclitaxel against various types of tumors, such as oophoroma, mastocarcinoma, carcinoma of colon and rectum, and lung cancer. A semi-synthesized homologue of paclitaxel, called docetaxel (tradename: Taxotere;
manufactured and sold by Rhone-Poulenc Rorer Pharmaceu-ticals Limited, U.S.A./France), has also been found to have good antitumor activities.
One of the defects of taxane compounds, a repre-sentative example of which is paclitaxel, is poor solubility in water. Therefore, paclitaxel needs to be formulated into a pharmaceutical composition by use of a non-aqueous adjuvant for dissolving medicines. One of the dissolving adjuvants, which are currently used, is Cremophor EL (manufactured and sold by Sigma, U.S.A.). However, Cremophor EL itself may cause unde-sirable adverse side effects, such as anaphylaxis in human. For that reason, a lot of researches have been made with respect to water-soluble derivatives of paclitaxel. For example, the technique of using phos-phonooxymethyl ether derivatives of taxane compounds [Unexamined Japanese Patent Application Laid-Open Specification (Japanese Kokai) No. 7-149779] and the technique of using carbonate type and ester type pro-drugs of taxane compounds having a leaving moiety which can be removed under basic conditions [Nature, 365, 464-466 (1993)] are known. However, satisfactory techniques have not yet been developed with respect to Prodrugs of taxane compounds.
In the techniques to improve various defects of a drug by chemically modifying the molecular structure of the drug, the effectiveness of the prodrug comprising a drug having bonded thereto a leaving moiety depends heavily on the selection of the mode of a bonding _ between the drug and the leaving moiety [see "Doraggu Deribarii Sisutemu" (Drug Delivery System), edited by Hitoshi Sezaki and published by Nankodo, Japan]. In general, when it is intended to restore a drug from a Prodrug by utilizing an enzymatic reaction, the types of enzymes distributed broadly in a living body, such as an esterase, an amidase and a carbamidase, will be determining factors for selecting the appropriate bonding mode. Therefore, when the drug has a hydroxyl group, the bonding mode is frequently selected among a carboxylic ester bond, a phosphoric ester bond and an acyloxymethyl ether bond, and when the drug has a carboxyl group, the bonding mode is frequently selected between an ester and an amide bond.
On the other hand, in general, high molecular weight compounds exhibit various unique properties and functions and, therefore, interact with a living body in manners which are largely different from the manners in which low molecular weight compounds interact with a living body. Therefore, a large number of attempts have been made, in which a drug having a low molecular weight is bonded to a high molecular weight compound as a leaving moiety to thereby produce a prodrug and the prodrug is used so as to control the behavior of the drug in a living body and the interactions between the drug and cells. Also in this case, the selection of the mode of a bonding between the drug and the high molecular weight compound is an important factor of determining the effectiveness of the prodrug. Usually, in a prodrug comprising a drug having bonded thereto a leaving moiety, the functional group of the drug is directly bonded to the functional group of the leaving moiety. It is still rare that a prodrug is constructed such that the drug is bonded to the leaving moiety through a spacer.

With respect to examples of such prodrugs compris-ing a drug, a spacer and a leaving moiety, although the number of examples thereof is small, there can be mentioned an example in which a carboxymethylated 5 dextran (carboxymethyldextran), which is a high molecu-lar weight polysaccharide, is used as a carrier. In this example of prodrug, doxorubicin having an amino group in the structure thereof is used as a drug, wherein a carboxymethyl dextran is introduced into the amino group of doxorubicin through the spacer (see, International Application Publication No. WO 94/19376).
As mentioned above, doxorubicin has an amino group in the structure thereof. In this technique, a peptide is used as a spacer. Therefore, each of the mode of the bonding formed between the amino group of the spacer and the carboxyl group of the carboxymethyldextran and the mode of the bonding formed between the carboxyl group of the spacer and the amino group of the drug is an amide bond. However, an amide bond is extremely stable in blood and, therefore, the rate of the release of the drug from the drug complex (prodrug) is very low in blood. Further, it is noted that, in this WO publi-ration, there is no description with respect to the release of a drug having a hydroxyl group.
As examples of prodrugs containing a synthetic polymer as a carrier, there can be mentioned prodrugs comprising doxorubicin as a drug, in which a high molecular weight compound (HPMA) (which is a product of copolymerization of a plurality of hydroxypropyl metha-crylamide derivatives) is bonded to doxorubicin at the amino group thereof through a peptide as a spacer [see, J. Contr. Rel., 10, 51-63 (1989), J. Contr. Rel., 19, 331-346 (1992), Eur. J. Cancer, 31A (suppl 5), S193 (1995)]. In these examples also, each of the mode of each of the bonding between the drug and the spacer and the mode of the bonding between the spacer and the carrier is an amide bond. Further, as mentioned above, the carrier is a synthetic polymer. Therefore, it is predicted that the carrier would not be degraded (metabolized) at all in a living body. As a result, when a drug complex (prodrug) containing the above-mentioned synthetic polymer as a carrier is adminis-tered to a living body, there is a danger of the ac-cumulation of the toxicity and antigenicity of the carrier because the carrier stays as a foreign sub-stance in a living body for a long period of time.
Therefore, the molecular weight of the carrier should be controlled to a level such that the carrier is not accumulated in a living body, but can be excreted rapidly.
As another example of a prodrug containing, as a carrier, a synthetic polymer produced in substantially the same manner as mentioned above, there can be men-tinned a prodrug comprising paclitaxel (a drug having hydroxyl groups) as a drug, in which a high molecular weight compound (HPMA) (which is a product of copoly-merization of a plurality of hydroxypropylmethacryla-mide derivatives) is bonded to the paclitaxel at least at one of the hydroxyl groups thereof through a peptide as a spacer (see, U.S. Patent No. 5,362,831). In this case also, since the carrier is a synthetic polymer, it is predicted that the carrier would not be degraded at all in a living body. As a result, when a drug complex (prodrug) having the above-mentioned synthetic polymer as a carrier is administered to a living body, there is a danger of the accumulation of the toxicity and anti-genicity of the carrier because the carrier stays as a foreign substance in a living body for a long period of time. Therefore, the molecular weight of the carrier should be controlled to a level such that the carrier is not accumulated in a living body, but can be excret-ed rapidly.
Further, as still another example of a prodrug containing a synthetic polymer as a carrier, there can be mentioned a prodrug comprising paclitaxel (a drug having hydroxyl groups) as a drug, and a polyethylene glycol having introduced thereinto a carboxyl group (hereinafter, simply referred to as "PEG-COON"), in which a PEG-COOH is bonded, at the carboxyl group thereof, directly to the paclitaxel at least at one of the hydroxyl groups thereof through an ester bond [see, Bioorganic & Medicinal Chemistry Letters, Vol. 4, No.
20, 2465-2470 (1994)]. In this case, the water-so-lubility of paclitaxel has been improved by bonding paclitaxel to a PEG-COOH so as to form a prodrug.
However, although the prodrug thus formed is stable in a buffer, the ester bond of the prodrug is likely to be rapidly cleaved in blood. Therefore, this prodrug (comprising a drug having bonded thereto a polymer by chemical modification) is still unsatisfactory for attaining the purpose of stably delivering the drug to a target site in a living body.
As apparent from the above, in the techniques of delivering a drug in the form of a prodrug comprising a carrier having bonded thereto a drug through a chemical bond, especially when the chemical bond is an ester bond, the rapid cleavage of an ester bond by an ester-ase or the like present is likely to occur in a living body. Therefore, the problems of the difficulty of the control of the rate of the release of a drug from a drug complex (prodrug) have not yet been fully solved.
SUMMARY OF THE INVENTION
In this situation, the present inventors have made extensive and intensive studies toward developing a drug complex which is capable of controlling the rate of the release of a drug therefrom, and which is ob-tained by introducing a spacer into the drug and then bonding the introduced spacer to a carrier.
As a result, it has unexpectedly been found that, when a drug complex of a drug having a hydroxyl group is constructed such that it comprises at least one a carrier having at least one carboxyl group, at least one spacer having at least one amino group and at least one carboxyl group, and at least one drug having a hydroxyl group, wherein the spacer is introduced to the drug through an ester bond formed between the hydroxyl group of the drug and the carboxyl group of the spacer, and wherein the spacer is bonded to the carrier through an amide bond formed between the amino group of the spacer and the carboxyl group of the carrier, the so constructed drug complex is capable of controlling the rate of the release of the drug from the drug complex.
It has also been found that a very effective control of the rate of the release of the drug from the drug complex can be achieved by appropriately selecting at least one spacer having a substituent X at the a-position relative to the carboxyl group of the spacer, wherein the substituent X has a specific Es value.
5 It has also been found that, when a drug complex of a drug having a hydroxyl group is constructed such that it comprises at least one carrier having at least one carboxyl group, at least one spacer having at least one amino group and at least one carboxyl group and 10 having a substituent X at the a-position relative to the carboxyl group thereof, and at least one water-insoluble drug having a hydroxyl group, such as a taxane compound, wherein the spacer is introduced to the drug through an ester bond formed between the hydroxyl group of the drug and the carboxyl group of the spacer, wherein the spacer is bonded to the carrier through an amide bond formed between the amino group of the spacer and the carboxyl group of the carrier, and wherein the spacer is selected so that substituent X
has a specific Es value, the so constructed drug com-plex is capable of not only controlling the rate of the release of the drug from the drug complex, but also improving the water-solubility of the drug, so that not only can the transferability of the drug to target tissues, such as tumor tissues, be enhanced, but also the exertion of the effect of the drug can be con-trolled.
Further, it has been found that, when the drug complex has a structure in which a taxane compound is used as the drug, a spacer is introduced into the 2'-or 7-positioned hydroxyl group of the taxane compound through an ester bond, and a carboxyalkyldextran is used as the carrier, the so constructed drug complex is capable of not only extremely improving the water-solubility of the taxane compound, but also decreasing the rate of the disappearance of the taxane compound in blood, and increasing the transferability of the drug to tumor tissues, thereby enhancing the effect of the taxane compound.
Still further, it has been found that, when the drug complex has a structure in which at least one steroid having a primary hydroxyl group, such as beta-methasone or prednisolone, is used as the drug, at least one spacer (such as an amino acid) having a substituent X at the a-position relative to the carbox-yl group thereof, wherein the spacer is appropriately selected so that the substituent X has a specific Es value, is introduced into the primary hydroxyl group of the steroid through an ester bond, and a carboxyalkyl-monosaccharide or an aliphatic carboxylic acid, such as acetic acid and propionic acid, is used as the carrier, the so constructed drug complex is capable of control-ling the rate of the release of the steroid from the drug complex in a living body, whereas, in a compound (drug complex) prepared by directly bonding a carbox-yalkylmonosaccharide as a carrier, [use of a carboxyal-kylmonosaccharide as a carrier has been reported in Chem. Pharm. Bull., 42(10), 2090-2096(1994)], or an aliphatic carboxylic acid, such as acetic acid and propionic acid, as a carrier, to the primary hydroxyl group of the steroid, such as betamethasone or predni-solone, through an ester bond, the release of the steroid from the compound is disadvantageously rapid.
Furthermore, it has been found that, when the drug complex has a structure in which at least one paclitax-el having hydroxyl groups is used as the at least one drug, at least one spacer (such as an amino acid) having a substituent X at the a-position relative to the carboxyl group thereof, wherein the spacer is appropriately selected so that the substituent X has a specific Es value, is introduced into one of the hy-droxyl groups of the paclitaxel through an ester bond, and a PEG-COOH is used as the carrier, the so con-strutted drug complex is capable of controlling the rate of the release of paclitaxel from the drug complex in a living body, whereas, in a compound prepared by directly bonding PEG-COOH as a carrier to the hydroxyl group of a drug having hydroxyl groups through an ester bond in a conventional manner, the release of the drug from the compound is disadvantageously rapid in a plasma of rat or human, although the compound is so stable in a buffer that the half-life of the above-mentioned compound in a buffer is 3 hours or more [see J. Med. Chem., 39, 1938-1940(1996)].
The present invention has been completed, based on the above novel findings.
Accordingly, it is an object of the present inven-tion to provide a drug complex of a drug which is capable of not only surely controlling the rate of the release of the drug from the drug complex, but also_ enhancing the transferability of the drug to the target tissues and the effectiveness of the drug.
It is another object of the present invention to provide a drug complex comprising a taxane compound as a drug, wherein the drug complex is not only capable of extremely improving the solubility of the taxane com-pound in water, but also surely controlling the rate of the release of taxane compound from the drug complex and enhancing the transferability of the taxane com-pound to the target tissues and the effectiveness of the taxane compound.
It is still another object of the present inven-tion to provide a medicine, which comprises the above-mentioned drug complex.
The foregoing and other objects, features and advantages of the present invention will be apparent to those skilled in the art from the following detailed description and appended claims taken in connection with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:
Fig. 1 is a chart showing the gel filtration chromatogram of carboxymethylated dextran sodium salt (1) obtained in Example 1, wherein the chromatogram_was obtained using an ultraviolet detector (wavelength: 214 nm).
Fig. 2 is a chart showing the gel filtration chromatogram of carboxymethylated dextran sodium salt (1) obtained in Example 1, wherein the chromatogram was obtained using a differential refractometer as a detec-tor.
Fig. 3 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Gly-pacli-taxel (3) obtained in Example 1, wherein the chromatogram was obtained using an ultraviolet detector (wavelength: 227 nm).
Fig. 4 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Gly-5 paclitaxel (3) obtained in Example 1 (concentration:
672 ug/ml, solvent: water).
Fig. 5 is a chart showing the ultraviolet absorp-tion spectrum of PEG-2'-Gly-paclitaxel (5) obtained in Example 1 (concentration: 205 ug/ml, solvent: water).
10 Fig. 6 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Ala-pacli-taxel (7) obtained in Example 2, wherein the chromato-gram was obtained using an ultraviolet detector (wave-length: 227 nm).
15 Fig. 7 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Ala-paclitaxel (7) obtained in Example 2 (concentration:
698 ug/ml, solvent: water).
Fig. 8 is a chart showing the ultraviolet absorp-tion spectrum of PEG-2'-Ala-paclitaxel (9) obtained in Example 2 (concentration: 204 ug/ml, solvent: water).
Fig. 9 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Leu-pacli-taxel (11) obtained in Example 3, wherein the chromato-gram was obtained using an ultraviolet detector (wave-length: 227 nm).
Fig. 10 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Leu-paclitaxel (11) (concentration: 644 um/ml, solvent:
water).
Fig. 11 is a chart showing the ultraviolet absorp-tion spectrum of PEG-2'-Leu-paclitaxel (13) obtained in Example 3 (concentration: 209 ug/ml, solvent: water).
Fig. 12 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Ile-pacli-taxel (15) obtained in Example 4, wherein the chromato-gram was obtained using an ultraviolet detector (wave-length: 227 nm).
Fig. 13 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Ile-paclitaxel (15) obtained in Example 4 (concentration:
628 ug/ml, solvent: water).
Fig. 14 is a chart showing the ultraviolet visible absorption spectrum of PEG-2'-Ile-paclitaxel (17) obtained in Example 4 (concentration: 214 ug/ml, sol-vent: water).
Fig. 15 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Phe-pacli-taxel (19) obtained in Example 5, wherein the chromato-gram was obtained using an ultraviolet detector (wave-length: 227 nm).
Fig. 16 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Phe-paclitaxel (19) obtained in Example 5 (concentration:
814 ug/ml, solvent: water).
Fig. 17 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Phe-Gly-paclitaxel (21) obtained in Example 6, wherein the chromatogram was obtained using an ultraviolet detector (wavelength: 227 nm).
Fig. 18 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Phe-Gly-paclitaxel (21) obtained in Example 6 (concentration:
940 ug/ml, solvent: water).
Fig. 19 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Gly-Phe-paclitaxel (23) obtained in Example 7, wherein the chromatogram was obtained using an ultraviolet detector (wavelength: 227 nm).
Fig. 20 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Gly-Phe-paclitaxel (23) obtained in Example 7 (concentration:
854 ug/ml, solvent: water) Fig. 21 is a chart showing the ultraviolet absorp-tion spectrum of PEG-isoleucyl-21-dexamethasone (25) obtained in Example 8 (concentration: 245 ug/ml, sol-vent: water).
Fig. 22 is a chart showing the ultraviolet absorp-tion spectrum of PEG-glycyl-21-dexamethasone (27) obtained in Example 8 (concentration: 201 ug/ml, sol-vent: water).
Fig. 23 is a chart showing the ultraviolet absorp-tion spectrum of PEG-alanyl-21-dexamethasone (29) obtained in Example 8 (concentration: 163 ug/ml, sol-vent: water).
Fig. 24 is a chart showing the ultraviolet absorp-tion spectrum of PEG-21-dexamethasone (31) obtained in Example 8 (concentration: 227 ug/ml, solvent: water).
Fig. 25 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-2'-Gly-Gly-Phe-Gly-paclitaxel (33) obtained in Example 9 (concen-tration: 700 ug/ml, solvent: water).
Fig. 26 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-2'-Gly-Gly-Phe-Gly-paclitaxel (33) obtained in Example 9, wherein the chromatogram was obtained using an ultraviolet detector (wavelength: 220 nm).
Fig. 27 is a chart showing the ultraviolet absorp-tion spectrum of carboxymethylated dextran-7-Gly-Gly-Phe-Gly-paclitaxel (35) obtained in Example 10 (concen-tration: 428 ug/ml, solvent: water).
Fig. 28 is a chart showing the gel filtration chromatogram of carboxymethylated dextran-7-Gly-Gly-Phe-Gly-paclitaxel (35) obtained in Example 10, wherein the chromatogram was obtained using an ultraviolet detector (wavelength: 220 nm).
Fig. 29 is a graph showing the changes (with the lapse of time) of the release of paclitaxel from com-pounds (3), (7), (11) and (15) in mouse serum at 37 °C, wherein the changes were measured in Experiment 2.
Fig. 30 is a graph showing the changes (with the lapse of time) of the release of paclitaxel from com-pounds (3), (7), (11) and (15) in human serum at 37 °C, wherein the changes were measured in Experiment 2.
Fig. 31 is a graph showing the antitumor effects of compounds (3), (7) and (15), wherein the effects were evaluated in Experiment 3 by antitumor assay, using tumor-transplanted mice.
Fig. 32 includes two graphs showing the changes (with the lapse of time) of the release of paclitaxel from compounds (3) and (19), and (21) and (23) in mouse serum at 37 °C, wherein the changes were measured in Experiment 4.
Fig. 33 is a graph showing the changes (with the lapse of time) of the release of paclitaxel from com-pounds (21) and (23) in human serum at 37 °C, wherein the changes were measured in Experiment 4.
Fig. 34 is a graph showing the changes (with the lapse of time) of the release of a drug from compounds (5), (9), (13) and (17) in mouse serum at 37 °C, wher-ein the changes were measured in Experiment 6.
Fig. 35 is a graph showing the changes (with the lapse of time) of the release of a drug from compounds (5), (9), (13) and (17) in human serum at 37 °C, wher-10 ein the changes were measured in Experiment 6.
Fig. 36 is a graph showing the changes (with the lapse of time) of the release of a drug from compounds (33) and (35) in mouse serum at 37 °C, wherein the changes were measured in Experiment 9.
15 Fig. 37 is a graph showing the results of the _ antitumor assays conducted in Experiment 10, i.e., the relationship between the doses of compound (33) and the relative average tumor volumes (%) which is measured after six days from the intravenous administration of 20 the test sample solution.
Fig. 38 is a graph showing the results of the antitumor assays conducted in Experiment 11, i.e., the changes (with the lapse of time) in the average tumor volume with respect to mice which had received the administrations of each of the test sample solution, the control solution and the physiological saline.
DETAILED DESCRIPTION OF THE INVENTION
Essentially, according to the present invention, there is provided a drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, the drug complex comprising:
(A) at least one carrier selected from the group consisting of saccharides each having at least one carboxyl group, polyethylene glycols each having at least one carboxyl group, straight or branched C2-C8 aliphatic carboxylic acids each having at least one carboxyl group, and derivatives thereof each having at least one carboxyl group;
(B) at least one spacer comprised of a compound having at least one amino group and at least one car-boxyl group; and (C) at least one drug having a hydroxyl group, wherein the at least one drug (C) is bonded to the at least one spacer (B) through an ester bond formed between the hydroxyl group of the drug (C) and the carboxyl group of the spacer (B) to form at least one drug-spacer block, and wherein the at least one drug-spacer block is bonded to the at least one carrier (A) through an amide bond formed between the amino group of the spacer (B) of the at least one drug-spacer block and the carboxyl group of the at least one carrier (A).
For easy understanding of the present invention, the essential features and various embodiments of the present invention are enumerated below.
1. A drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, the drug complex comprising:
(A) at least one carrier selected from the group consisting of saccharides each having at least one carboxyl group, polyethylene glycols each having at least one carboxyl group, straight or branched C2-C8 aliphatic carboxylic acids each having at least one carboxyl group, and derivatives thereof each having at least one carboxyl group;
(B) at least one spacer comprised of a compound having at least one amino group and at least one car-boxyl group; and (C) at least one drug having a hydroxyl group, wherein the at least one drug (C) is bonded to the at least one spacer (B) through an ester bond formed between the hydroxyl group of the drug (C) and the carboxyl group of the spacer (B) to form at least one drug-spacer block, and wherein the at least one drug-spacer block is bonded to the at least one carrier (A) through an amide bond formed between the amino group of the spacer (B) of the at least one drug-spacer block and the carboxyl group of the at least one carrier (A).
2. The drug complex according to item 1 above, wher-ein the hydroxyl group of the at least one drug (C), which is bonded to the carboxyl group of the at least one spacer (B) to form the ester bond, is a primary hydroxyl group, and the at least one spacer (B) has a substituent X at the a-position relative to the carbox-yl group of the at least one spacer (B), wherein the substituent X has a steric hindrance parameter (Es) value of from -1.0 to -2.5, the Es value being defined by the following formula (1):
Es = log (kX/kH) (1) wherein kX is the reaction rate constant for the acid hydrolysis reaction of an a-monosub-stituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COORx + H20 -> X-CH2COOH + RxOH
wherein X is as defined above and Rx is a group selected from the group consisting of Cl-C18 alkyl groups and C6-C18 aryl groups;
and kH is the reaction rate constant for the acid hydrolysis reaction of an unsubstituted acetic acid ester corresponding to the a monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
_ CH3COORy + H20 -> CH3COOH + R~'OH
wherein Ry has the same meaning as defined for Rx.
3. The drug complex according to item 1 above, wher-ein the hydroxyl group of the at least one drug (C), which is bonded to the carboxyl group of the at least one spacer (B) to form the ester bond, is a secondary hydroxyl group, and the at least one spacer (B) has a substituent X at the a-position relative to the carbox-yl group of the at least one spacer (B), wherein the substituent X has a steric hindrance parameter (Es) value of from -0.0 to -2.5, the Es value being defined 5 by the following formula (1):
Es = log (kX/kH) (1) wherein kX is the reaction rate constant for 10 the acid hydrolysis reaction of an a-monosub-stituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
15 X-CH2COORx + H20 -> X-CH2COOH + RXOH
wherein X is as defined above and Rx is a group selected from the group consisting of Cl-C18 alkyl groups and C6-C18 aryl groups;
20 and kH is the reaction rate constant for the acid hydrolysis reaction of an unsubstituted acetic acid ester corresponding to the a-monosubstituted acetic acid ester, wherein 25 the acid hydrolysis reaction is represented by the following formula:
CH3COORy + H20 -> CH3COOH + RyOH
wherein Ry has the same meaning as defined for Rx.
4. The drug complex according to item 1 above, wher-ein the carrier (A) is selected from the group consist-ing of polysaccharides each having at least one carbox-yl group and derivatives thereof each having at least one carboxyl group.
5. The drug complex according to item 4 above, wher-ein the carrier (A) is a carboxyalkyldextran.
6. The drug complex according to item 1 above, wher-ein the at least one carrier (A) is selected from the group consisting of monosaccharides each having at least one carboxyl group and derivatives thereof each having at least one carboxyl group.
7. The drug complex according to item 1 above, wher-ein the at least one spacer (B) is selected from the group consisting of glycine, alanine, leucine, isoleu-tine and phenylalanine.
8. The drug complex according to any one of items 1 above, 3, 4, 5, 6 and 7, wherein the at least one drug (C) is selected from the group consisting of taxane compounds.
9. The drug complex according to any one of items 1 above, 2, 4, 5, 6 and 7, wherein the at least one drug (C) is selected from the group consisting of steroids.
10. A medicine comprising the drug complex of any one of items 1 to 9 above.
11. The drug complex according to item 1 above, wher-ein:
the drug (C) is at least one taxane compound represented by the following formula (2):
a o R2 R3 R4 R1-CO-NH i o 9~~ [.....,.,,,Rs 3. 2. 7 (2) Ph 0......,.,........ 1 3 5 '' 2 5 0 H 1 H~0 2 _ OH OAc OCOPh wherein R1 represents a group selected from the group consisting of a straight or branched C1-C6 alkyl group, a straight or branched C2-C6 alkenyl group, a straight or branched C2-C6 alkynyl group, a straight or branched C1-C6 alkoxy group and an unsub-stituted or substituted phenyl group; R2 represents a group selected from the group consisting of a hydrogen atom, a hydroxyl group and an acetyloxy group; one of R3 and R4 represents a hydrogen atom and the other represents a hydroxyl group, or R3 and R4 together form an oxo group; one of R5 and R6 represents a hydrogen atom and the other represents a hydroxyl group; Ac represents an acetyl group; and Ph represents a phenyl group, the at least one taxane compound of formula (2) is bonded, at the 2'- or 7-positioned hydroxyl group thereof, to the at least one spacer (B) at the carboxyl group thereof through the ester bond formed between the hydroxyl group and the carboxyl group, the carrier (A) is a carboxyalkyldextran repre-sented by the following formula (3):
(3) 10 wherein each of R~, R8 and R9 independently represents a hydrogen atom or a carboxylal-kyl group selected from the group consist-ing of -(CH2)m-COOH, -CH(CH3)-COOH, -CH2CH(CH3)-COOH and -CH(CH3)CH2-COOH, wherein m represents an integer of from 1 to 4; and n represents an integer of from 50 to 1000, with the proviso that the ratio of the number of carboxylalkyl groups to the number of n is 0.1 to 2.0, and the carboxyalkyldextran is bonded, at the carboxyl moiety of at least one of the carboxyalkyl groups thereof, to the at least one spacer (B) at the amino group thereof through the amide bond formed between the amino group and the carboxyl group.

12. The drug complex according to item 11 above, wherein the at least one spacer (B) has a substituent X
at the a-position relative to the carboxyl group, wherein the substituent X has a steric hindrance param-5 eter (Es) value of from -0.0 to -2.5, the Es value being defined by the following formula (1):
Es = log (kX/kH) (1) 10 wherein kX is the reaction rate constant for the acid hydrolysis reaction of an a-monosub-stituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COORx + H20 -> X-CH2COOH + RXOH
wherein X is as defined above and Rx is a group selected from the group consisting of C1-Clg alkyl groups and C6-C18 aryl groups;
and kH is the reaction rate constant for the acid hydrolysis reaction of an unsubstituted acetic acid ester corresponding to the a-monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
CH3COORy + H20 -> CH3COOH + RyOH
wherein Ry has the same meaning as defined for Rx.
13. The drug complex according to item 11 or 12 above, wherein the drug (C) is at least one paclitaxel.
14.. The drug complex according to item 11 or 12 above, wherein the drug (C) is at least one docetaxel.
15. An antitumor medicine, which comprises the drug complex of any one of items 11 to 14 above.
With respect to the drug used in the present invention, there is no particular limitation, as long as the drug has a hydroxyl group. With respect to the type of the hydroxyl group, there is no particular limitation, and the hydroxyl group may be either a primary, hydroxyl group or a secondary hydroxyl group.
In the present invention, the term "primary hydroxyl group" means a hydroxyl group directly bonded to a primary carbon atom, such as a hydroxyl group of etha-nol or 1-butanol, and the term "secondary hydroxyl group" means a hydroxyl group directly bonded to a secondary carbon atom, such as a hydroxyl group of 2-propanol or 2-butanol. Examples of drugs having a primary hydroxyl group, which can be used in the pres-ent invention, include betamethasone, prednisolone, dexamethasone (each of which is a steroid) and the like. On the other hand, examples of drugs having a secondary hydroxyl group, which can be used in the present invention include taxane compounds represented by the following formula (2):
R2 R3. R4 R~ _ Cp -NH ~ 0 9 ~~ R5,'\,R6 _ 0 ~ L ...., 2. 7 Ph 3 ' p...,..,.......... ,. 3 s ( 2 ) ...,,,, OH H~0 OH OAc OCOPh wherein R1 represents a group selected from the group consisting of a straight or branched C1-C6 alkyl group, a straight or branched C2-C6 alkenyl group, a straight or branched C2-C6 alkynyl group, a straight or branched C1-C6 alkoxy group and an unsub-stituted or substituted phenyl group; R2 represents a group selected from the group consisting of a hydrogen atom, a hydroxyl group and an acetyloxy group; one of R3 and R4 represents a hydrogen atom and the other represents a hydroxyl group, or R3 and R4 together form an oxo group; one of R5 and R6 represents a hydrogen atom and the other represents a hydroxyl group; Ac represents an acetyl group; and Ph represents a phenyl group.
As specific examples of taxane compounds, there can be mentioned paclitaxel (tradename: Taxol; manufac-tured and sold by Brystol-Myers Squibb, U.S.A.) repre-sented by the following formula (4) and docetaxel (tradename: Taxotere; manufactured and sold by Rhone-Poulenc Rorer Pharmaceuticals Limited, U.S.A./France) represented by the following formula (5). Further, derivatives of paclitaxel and docetaxel are also in-cluded in the taxane compounds which can be used in the present invention.

Ac0 0 OH
Ph-CO-HN 1 °

(4), and ph 3 ~ 2 r pnn~~~~~~~.,.... 1 3 0H "'''~ ~:~'0 OH OAc OCOPh to HO 0 (5).
tBu-0-CO-HN OH
0 ~° ~ I
Ph 3.' 2 = 1 3 5 ~ -OH °''' - ;
H
OH OAc OCOPh The spacer which can be used in the present inven-tion comprises a compound having at least one amino group and at least one carboxyl group in a molecular structure. In the drug complex, such a spacer having bonded thereto a drug can usually release the drug or active molecular species thereof therefrom rapidly or, occasionally, gradually by the action of enzymes pres-ent in organs, such as a protease, a peptidase and an esterase. As examples of such spacers, there can be 5 mentioned amino acids occurring in proteins, amino acids not occurring in proteins, and peptides compris-ing these amino acids, wherein mutually adjacent two amino acids contained in the peptide are bonded through a peptide (amide) bond.
10 In the present invention, the term "amino acid occurring in proteins" means a constituent amino acid of proteins, such as glycine, alanine, phenylalanine, leucine, isoleucine or the like. On the other hand, the term "amino acid not occurring in proteins" means 15 an amino acid other than constituent amino acids of-proteins, such as norleucine, norvaline, hydroxypro-line, pyroglutamic acid, a-cyclohexylalanine, a-ala-nine, E-aminocaproic acid, 7-aminobutyric acid or the like.
20 In the present invention, when a compound having a substituent X at the a-position relative to the carbox-yl group of the compound is used as a spacer, the magnitude of the steric hindrance caused by the substi-tuent X has a great influence on the rate of the re-25 lease of the drug from the drug complex of the present invention. Therefore, the rate of the release of the drug from the drug complex can be controlled by appro-priately selecting a spacer having a substituent X at the a-position relative to the carboxyl group, wherein the substituent X has a specific magnitude of steric hindrance.
In general, in a chemical reaction, when a substituent is present in the neighborhood of the center of the reaction, the substituent has various effects on the progress of the reaction. Steric hin-drance is one of these effects. The term "steric hindrance" means such an effect that the presence of a bulky substituent X in the neighborhood of the center of the reaction inhibits the progress of the chemical reaction. It is considered that the bulky substituent X present in the neighborhood of the center of the reaction inhibits the approach of a reagent to the center of the reaction, so that the steric hindrance occurs. The magnitude of the steric hindrance depends on the bulkiness of the substituent X.
As a value for numerically expressing the magni-tude of the steric hindrance of a substituent, the so-called ."Es value" defined by Taft et al. is known (American Chemical Society Professional Reference Book, "Exploring QSAR", written by C. Hansch and A. Leo and edited by S. R. Hell). The rate of the release of the drug from the drug complex can be effectively con-trolled by selecting a spacer having a substituent X at the a-position relative to the carboxyl group of the spacer, wherein the substituent X has a specific Es value. Explanation on the Es value is made below.
From the results of various experiments, it is known that, in the acid hydrolysis reaction of an ester, the effect of the substituent of the ester on the progress of the reaction can be considered to be the steric hindrance only. This known fact was utilized for numerically expressing the magnitude of the steric hindrance of the substituent. Thus, a concept of the "Es value" has been established.
The Es value of a substituent X can be determined by the following formula (1):
Es = log (kX/kH) (1) wherein kX is the reaction rate constant for the acid hydrolysis reaction of an a-monosub-stituted acetic acid ester which is derived from an a-monosubstituted acetic acid ob-tamed by substituting one hydrogen atom of the methyl group of acetic acid with a sub-stituent X, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COORx + H20 -> X-CH2COOH + RXOH
wherein X is as defined above and RX is a group selected from the group consisting of C1-ClB alkyl groups and C6-C18 aryl groups;
and kH is the reaction rate constant for the acid hydrolysis reaction of an acetic acid ester corresponding to the above-mentioned a-mono-substituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
CH3COORy + H20 -> CH3COOH + RyOH
wherein Ry has the same meaning as define for Rx.
The reaction rate is lowered by the steric hin-drance caused by the substituent X and, therefore, kX
is smaller than kH, so that the Es value usually becomes negative.
When the Es value is actually determined, first, the above-mentioned two reaction rate constants for the acid hydrolysis reaction, i.e., kX and kH, are deter-s mined, followed by calculation of the Es value by formu-la (1) described above. In the above-mentioned text-book (American Chemical Society Professional Reference Book, 'Exploring QSAR' p.81 Table 3-3), specific exam-ples of Es values obtained by the actual measurements are described. Some examples of Es values are shown below.
Types of substituents X Es values H 0 (standard) CH3 -1.24 CH2C6H5 -1.61 CH2CH(CH3)2 -2.17 CH(CH3)CH2CH3 -2.37 In the present invention, as mentioned above, an amino acid occurring in proteins can be used as a spacer. The amino acids having the substituents shown above at the a-positions relative to the carboxyl groups thereof are glycine (Gly), Alanine (Ala), Pheny-lalanine (Phe), Leucine (Leu) and isoleucine (Ile).

When, among these amino acids, Gly, Ala, Leu and Ile are arranged in the order of magnitude of Es value (in absolute value) of the substituent at the a-position relative to the carboxyl group thereof, the order can 5 be shown by Ile > Leu > Ala > Gly. That is, the magni-tude of the steric hindrance of the substituent of the amino acid becomes smaller in this order. Further, the magnitude of the steric hindrance of the substituent correlates with the rate of the release of the drug 10 from the drug complex of the present invention.
For example, with respect to the drug complexes which are so constructed that the spacer is Gly, Ala, Leu or Ile, the drug is paclitaxel, and the carrier is carboxymethyldextran, when the amino acids used as the 15 spacer in the drug complexes are arranged in the order of the rate of the release of the drug from the drug complex in a living body, the order can be shown by Gly > Ala > Leu > Ile.
On the other hand, with respect to the drug com-20 plexes which are substantially the same as mentioned above, except that the amino acids used as the spacer in the drug complexes are Gly or Phe, when the amino acids used as the spacer in the drug complexes are arranged in the order of the rate of the release of the 25 drug from the drug complex in a living body, the order can be shown by Gly > Phe.
Therefore, with respect to the above-mentioned drug complexes, the Es value (i.e., the magnitude of the steric hindrance) of the substituent of the spacer at its a-position relative to the carboxyl group of the spacer has a correlation with the rate of the release of the drug.
In another example where the drug complexes are so constructed that the spacer is Gly, Ala, Leu or Ile, the drug is dexamethasone and the carrier is propionic acid, when the amino acids used as the spacer in the drug complexes are arranged in the order of the rate of the release of the drug in a living body, the order can be shown by Gly > Ala > Leu > Ile. Therefore, also with respect to the above-mentioned drug complexes,. the Es value (i.e., the magnitude of the steric hindrance) of the substituent of the spacer at its a-position relative to the carboxyl group of the spacer has a correlation with the rate of the release of the drug.
In still another example where the drug complexes are so constructed that the spacer is a peptide Gly-Phe or a peptide Phe-Gly, the drug is paclitaxel and the carrier is carboxymethyldextran, when the peptides used as the spacer in the drug complexes are arranged in the order of the rate of the release of the drug from the drug complex in a living body, the order can be shown by Phe-Gly > Gly-Phe. Therefore, also with respect to the above-mentioned drug complexes, the Es value (i.e., the magnitude of the steric hindrance) of the substitu-ent at the a-position relative to the carboxyl group of the spacer has a correlation with the rate of the release of the drug. Further, as apparent from the above, even in the case of the drug complex wherein the spacer is a peptide or the like, the important factor for the control of the rate of the release of the drug from the drug complex is the magnitude of the steric hindrance of the substituent of the spacer at its a-position relative to the carboxyl group of the spacer, wherein the carboxyl group of the spacer is bonded directly to the hydroxyl group of the drug in the drug complex.
The carrier which can be used in the present invention is selected from -the group consisting of saccharides each having at least one carboxyl group, polyethylene glycols each having at least one carboxyl group, straight or branched C2-C8 aliphatic carboxylic acids each having at least one carboxyl group, and derivatives thereof each having at least one carboxyl group.
with respect to the saccharides each having at least one carboxyl group and derivatives thereof each having at least one carboxyl group, which can be used in the present invention, there is no particular limi-tation as long as they have at lest one carboxyl group.
However, a carboxyalkylated dextran (carboxyalkyldex-trap) is especially preferred.
The carboxyalkyldextran which can be used in the present invention as a carrier has a structure wherein the hydrogen atom or atoms of part or all of the hydroxyl groups of dextran is/are substituted with a carboxyalkyl group, and the carboxyalkyldextran is composed mainly of a unit (a sugar residue) represented by the following formula (3):
(3) R94 I ~1 wherein each of R~, R$ and R9 independently represents a hydrogen atom or a carboxyal-kyl group selected from the group consist-ing of -(CH2)m-COOH, -CH(CH3)-COON, -CH2CH(CH3)-COOH and -CH(CH3)CH2-COOH, wherein m represents an integer of from 1 to 4; and n represents an integer of from 50 to 1000, with the proviso that the ratio of the number of carboxylalkyl groups to the number of n is 0.1 to 2Ø
Further, the carboxyalkyldextran may have a branched chain structure.
As examples of preferable carboxyalkyl groups, there can be mentioned a carboxymethyl group, a carbox-yethyl group, a carboxy-n-propyl group, a carboxyiso-propyl group, a carboxy-n-butyl group and the like.
With respect to the above-mentioned carboxyalkyl-dextran, the degree of introduction of the carboxyalkyl groups can be represented by the "degree of substitu-tion" defined as the number of the carboxyalkyl groups (including carboxyalkyl groups each having introduced thereto a peptide as a spacer) per saccharide residue.
That is, the degree of substitution of carboxyalkyldex-tran is represented by the following formula:

Total number of carboxyalkyl groups in the molecule of Degree of carboxyalkyldextran substitution of -carboxyalkyldextran Total number of sugar residues in the molecule of 5 carboxyalkyldextran Hereinafter, when a carboxyalkyl group is a car-boxymethyl group, the above-mentioned degree of substi-tution may be referred to as a "degree of carboxymethy-10 lation." With respect to a carboxyalkyldextran, when all of the hydrogen atoms of the hydroxyl groups are substituted with a carboxyalkyl group, the degree of substitution is 3. In the present invention, it is preferred that the degree of substitution is 0.1 or 15 more, more advantageously from 0.1 to 2.0 from the viewpoint of the pharmacokinetics of the drug in a living body.
A carboxyalkyldextran which can be preferably used as a carrier in the present invention can be obtained 20 bY introducing carboxyalkyl groups into hydroxyl groups of dextran. For example, dextran is dissolved in an appropriate solvent in the presence of alkali (for example, when water is used as the solvent, in the presence of sodium bicarbonate, potassium carbonate, 25 aqueous ammonia, sodium hydroxide or the like, and when an appropriate organic solvent, such as N,N-dimethyl-formamide, dimethylsulfoxide or the like is used as a solvent, in the presence of pyridine, triethylamine or the like), and monochloroacetic acid is then added thereto, followed by effecting a reaction at a tempera-ture of from an ice-cooled temperature to room tempera-ture for a period of from several minutes to several days, to thereby obtain a reaction mixture. Subse-quently, the pH value of the obtained reaction mixture is adjusted to 8 by adding thereto an acid, such as acetic acid, and the reaction mixture is added dropwise into ethanol, to thereby obtain a carboxymethyldextran as a precipitate. In this case, the "degree of substi-tution" of carboxyalkyldextran can be adjusted by changing the reaction solvent, reaction time, reaction temperature, or amount of monochloroacetic acid or alkali to be added.
In the present invention, when the carrier is selected from the group consisting of polyethylene glycols each having at least one carboxyl group and derivatives thereof each having at least one carboxyl group, it is preferred that the polyethylene glycol or derivative thereof has a molecular weight of from 1,000 to 40,000.
Hereinbelow, a description is made with respect to the method for producing the drug complex of the pre-sent invention. The drug complex of the present inven-tion is obtained by introducing at least one spacer into at least one drug thereby obtaining at least one drug-spacer block, followed by introducing the obtained at least one drug-spacer block into at least one carri-er. It is preferred that the synthetic reactions for producing the drug complex of the present invention are conducted under as mild conditions as possible in order to avoid the lowering of the activity of the drug or, in order to avoid the crosslinking or aggregation of the carrier in the synthetic processes when the carrier is a high molecular weight compound. From this point of view, for producing the drug complex of the present invention, it is preferred to use the same method as used in the peptide synthesis.
Now, a description is made with respect to the method for introducing a spacer into a drug to thereby obtain a drug-spacer block. In the present invention, the spacer is introduced into the drug by forming an ester bond between the carboxyl group of the spacer and the hydroxyl group of the drug.
The formation of an ester bond can be achieved by a method comprising reacting a predetermined amount of the drug and a predetermined amount of the spacer in a solvent which can be used for ordinary organic synthet-is reactions, such as methylene chloride, N,N-dimethylformamide, tetrahydrofuran or the like, in an amount sufficient for dissolving the drug, spacer and other reagents, in the presence of an appropriate condensing agent, such as N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-(3-dimethylamino-propyl)carbodiimide hydrochloride, 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline or the like, in an amount equivalent to the molar amount of the drug, and, if desired, in the presence of N,N-dimethylaminopyridine, in an amount equivalent to the molar amount of the drug or in a catalytic amount, at room temperature or under heating, if desired, in an atmosphere of dry inert gas, such as argon and helium, and under atmospheric pres-sure for a period of from several hours to several days. Further, it is preferred that, prior to the above-mentioned reaction, a functional group of the spacer or drug which may cause undesirable side reac-tions is protected by a protective group as used for peptide synthesis. For example, it is preferred that an amino group is protected by an Fmoc (9-fluorenyl-methyloxycarbonyl) group, a Trt [triphenylmethyl (trityl)] group, a Z (benzyloxycarbonyl) group or the like, that a carboxyl group is protected by a benzyl ester group, a tertially butyl ester group, a phenacyl ester group or the like, and that a hydroxyl group is protected by a benzyl ether group, a tertially butyl ether group or the like.
Next, description is made below with respect to the method for introducing the drug-spacer block into a carrier.
When the amino group of the spacer of the drug-spacer block is protected, the amino group of the spacer is deprotected by the method as used for peptide synthesis. For example, when a Z group is used as a protective group, deprotection can be achieved by hydrogenation in the presence of palladium, or the like. When an Fmoc group is used as a protective group, deprotection can be achieved by the treatment with piperidine or the like. When a Trt group is used as a protective group, deprotection can be achieved by the treatment with acetic acid or the like.
Subsequently, an amide bond is formed between the amino group of the spacer of the drug-spacer block and the carboxyl group of the carrier. The formation of the amide bond can be achieved by a method comprising reacting a predetermined amount of the drug-spacer block with a predetermined amount of the carrier in a solvent which can be used for ordinary organic synthet-is reactions, such as methylene chloride, N,N-dimethylformamide, tetrahydrofuran or the like (or, especially when the carrier is water-soluble, in a mixed solvent of water with a hydrophilic organic solvent, such as N,N-dimethylformamide, dimethylsulfox-ide or the like) in an amount sufficient for dissolving the drug-spacer block, carrier and other reagents [occasionally, in the presence of a predetermined amount of an appropriate condensing agent, such as 10 N,N'-dicyclohexylcarbodiimide, N,N'-diisopropylcarbodi-imide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, 1-ethoxycarbonyl-2-ethoxy-1,2-dihydro-quinoline or the like] at 4 °C or room temperature under atmospheric pressure for a period of from several 15 hours to several days. Further, the amount of the drug to be introduced into the drug complex can be con-trolled by changing the amount of the drug-spacer block relative to the amount of the carrier, the reaction time or the amount of the condensing agent.
20 In the present invention, with respect to the spacer used for bonding the carrier having at least one carboxyl group to the drug having a hydroxyl group, there is no particular limitation as long as it has at least one amino group and at least one carboxyl group.
25 Hereinbelow, description is made with respect to a peptide as an example of the spacer.
From the viewpoint of the preferred drug-releasing properties of the drug complex and avoidance of complicatedness of the synthetic process of a peptide, it is preferred that the peptide used as a spacer in the present invention comprises six amino acids residues or less, more advantageously four amino acid residues or less. Further, "a peptide comprising amino acids" includes a peptide comprising a compound (or compounds) other than amino acids as a part thereof, as well as a peptide consisting of only amino acids. For example, the peptide can comprise a dibasic carboxylic acid, such as succinic acid, in the peptide chain or at a terminus thereof. Further, an amino acid contained in the above peptide can be an_ amino acid other than an a-amino acid, such as an amino acid occurring in proteins. Examples of such other types of amino acids include ~-alanine, e-aminocaproic acid or y-aminobutylic acid. Further, with respect to the manner of bonding the peptide to the carrier, the peptide is usually bonded, at the amino group of the N-terminus thereof, to the carrier at the carboxyl group thereof through an amide bond. However, the peptide can be bonded to the carrier in such a manner that an amino acid having two amino groups is bonded, at one of the two amino groups thereof (e. g., at the E-amino group thereof when a peptide containing lysine is used) to a carrier at the carboxyl group thereof, that the amino acid having two amino groups is bonded, at the other amino group thereof, to the peptide at the car-boxyl group of the C-terminus thereof, thereby reversing the bonding direction of the peptide, and that an amino acid having two carboxyl groups, such as glutamic acid, is bonded, at one carboxyl group thereof, to the pep-tide at the amino group of the N-terminus thereof, and bonded, at the other carboxyl group thereof, to a drug at the hydroxyl group.
There is no particular limitation with respect to the types of the amino acids contained in the peptide, as long as the peptide has a structure such that the drug or corresponding active molecular species can be released rapidly or, if desired, gradually from the drug complex by the action of enzymes present in or-gans, such as a protease, a peptidase and an esterase.
The amino acid contained in the peptide can be a neu-tral, basic or acidic amino acid. In one preferred embodiment of the present invention, the peptide is Phe-Gly, or a peptide containing amino acid sequence -Phe-Gly- in the peptide chain. Such a peptide is bonded, at the amino group of the N-terminus thereof, to the carrier at the carboxyl group thereof through an amide bond.
Now, description is made with respect to the method for introducing a peptide into a taxane com-pound, as an example of the methods for introducing a peptide as a spacer into a drug for obtaining a drug-spacer block. In this case, the introduction of a peptide into a taxane compound is achieved by bonding the taxane compound, at the 2'- or 7-positioned hydrox-yl group thereof, to the peptide at the C-terminus thereof through an ester bond.
The introduction of a peptide into a taxane com-pound at the 2'-positioned hydroxyl group thereof can be achieved by reacting the peptide directly with the taxane compound in the presence of an appropriate .
condensing agent, such as N,N'-dicyclohexylcarbodii-mide, N,N'-diisopropylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline or the like. Further, it is preferred that prior to the above reaction, each of the N-terminus of the peptide and the functional groups of the side chain of the peptide which may cause side reactions is protected by protec-tive groups as used for peptide synthesis, such as an Fmoc (9-fluorenylmethyloxycarbonyl) group, a Trt [triphenylmethyl (trityl)) group, a Z (benzyloxycarbo-nyl) group or the like.
When a peptide is introduced into a taxane com-pound at the 7-positioned hydroxyl group thereof, the 2'-positioned hydroxyl group of the taxane compound is protected by an appropriate protective group, for example, which is frequently used for peptide synthe-sis, such as a Z group, followed by introduction of the desired peptide into the taxane compound at 7-posi-tinned hydroxyl group thereof in the same manner as mentioned above. In both of the above two cases, it is preferred that, after introduction of the protected peptide, the protective groups are removed under such conditions that the taxane compound is not decomposed, e~g-, by hydrogenation, or under weakly acidic or weakly basic conditions.
Next, as an example of the method for introducing a drug-spacer block into a carrier, description is made with respect to the method for introducing a drug-spacer block (which consists of a peptide as a spacer and a taxane compound having introduced thereinto the peptide at the 2'- or 7-positioned hydroxyl group thereof as obtained by the above-mentioned method) into a carboxyalkyldextran as a carrier. In this case, the introduction of the drug-spacer block into the carrier can be achieved by bonding the N-terminus of the pep-tide as a spacer to the carrier at the carboxyl group thereof through an amide bond. The formation of the amide bond can be achieved by reacting the carboxyal-5 kyldextran with the above-mentioned drug-spacer block in a mixed solvent of a hydrophilic organic solvent, such as N,N-dimethylformamide, dimethylsulfoxide or the like and water (occasionally, in the presence of an appropriate condensing agent, such as N,N'-dicyclohex-10 ylcarbodiimide, N,N'-diisopropylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride, 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, O-(7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) or the like).
15 Hereinbelow, description is made with respect to the drug introduction ratio and administration method of the drug complex, which comprises a drug having a hydroxyl group, a spacer having at least one amino group and at least one carboxyl group and a carrier 20 having at least one carboxyl group.
The drug introduction ratio into the carrier is appropriately selected depending on the type of the drug. However, generally, the drug introduction ratio is preferably from 1 to 30 o by weight, more preferably 25 from 1 to 15 % by weight, based on the weight of the drug complex, so that the preferable kinetics of the carrier in a living body can be reflected on the kinet-ics of the drug complex.
The drug complex obtained in the above-mentioned manner can be used in the same manner as in the case of the drug as such. The dose, dosage form and dosage schedule of the drug complex of the present invention are not particularly limited and may be varied depend-ing on the drug complex used. The drug complex of the present invention can be administered in any appro-priate route, preferably in a parenteral manner, and the dose of the drug complex may be varied depending on the composition of the formulation containing the drug complex, the administration route or the administration site for the drug complex, the species of the host, the disease to be treated or the like. Further, when the dose of the drug complex is selected, a variety of factors which may change the effectiveness of the drug, such as age, body weight, sex, diet and physical condi-tions of the patient and the like must be taken into consideration.
Hereinbelow, description is made of the drug introduction ratio, solubility and administration method with respect to one example of the drug complex of the present invention, wherein the drug is paclitax-el, the spacer is an amino acid or a peptide and the carrier is a carboxyalkyldextran.
Generally, the introduction ratio of paclitaxel into the carboxyalkyldextran is preferably from 1 to 30 % by weight, more preferably from 1 to 10 % by weight, based on the weight of the drug complex, so that the preferable kinetics of carboxyalkyldextran as a carrier in a living body can be reflected on the kinetics of the drug complex.
The above-obtained drug complex comprising a carboxyalkyldextran as a carrier, an amino acid or peptide as a spacer and paclitaxel as a drug shows extremely high water-solubility as compared to pacli-taxel per se. That is, the water-solubility of the above drug complex is as high as 1.6 mg/ml or more in terms of the solubility of paclitaxel, whereas the water-solubility of paclitaxel is reported to be less than 0.004 mg/ml [Nature, 365, 464-466 (1993)]. There-fore, in an antitumor assay, the drug complex of the present invention can be dissolved directly in a phys-iological saline without using a dissolving adjuvant, and can be administered intravenously.
The drug complex of the present invention can be used in the same manner as in the case of the drug per se. The dose, dosage form and dosage schedule of the drug complex of the present invention are not particu-larly limited and can be varied depending on the drug complex used. The drug complex of the present inven-tion can be administered in any appropriate route, preferably in a parenteral manner. When the drug is paclitaxel, the dose is, generally, approximately 20 to 1,000 mg/m2 of the total body surface area per day for an adult, in terms of the amount of paclitaxel. The actual dose can be varied depending on the composition of the formulation containing the drug complex, the administration route or the administration site for the drug complex, the species of the host, the tumor to be treated or the like. Further, when the dose of the drug complex is selected, a variety of factors which may change the effectiveness of the drug, such as age, body weight, sex, diet and physical conditions of the patient and the like must be taken into consideration.

BEST MODE FOR CARRYING OUT THE INVENTION
Hereinbelow, the present invention will be de-scribed in more detail with reference to the following Examples, Reference Examples and Experiments, which, however, should not be construed as limiting the scope of the present invention.
The compound numbers used in Examples correspond to the numbers used in the schemes showing synthetic processes mentioned below.
Further, the degree of carboxymethylation of polysaccharide derivative was determined by titration with alkali. The introduction ratio of the drug (weight $) was determined from the absorbance analysis of the drug (at a wavelength of 254 nm). Gel filtra-tion was conducted under the following conditions:
Column: TSKgel 64000 PWXZ (manufactured and sold by Tosoh Corporation, Japan);
eluate: 0.1 M Nacl;
flow rate: 0.8 ml/min.;
temperature of the column: 40 °C; and amount of the sample per injection: approximately 50 ug.
High resolution mass spectrum (hereinafter simply referred to as "HRMS") was obtained by fast atom bom-bardment mass spectrometry (FAB-MS) by means of a mass spectrometer HX-110 (manufactured and sold by JEOL, Ltd., Japan) using glycerin or a mixture of glycerin and 3-nitrobenzylalcohol as a matrix.
In the following Reference Examples and Examples, 5 the following abbreviations are used.
DMF: N,N-dimethylformamide Trt: triphenylmethyl (trityl) group Z: benzyloxycarbonyl group Fmoc: 9-fluorenylmethyloxycarbonyl group 10 PEG: poly (ethyleneglycol) methyl ether having a molecular weight of 5,000 tBuOK: Potassium t-butoxide DMSO-d6: deuterated dimethylsulfoxide 15 Example 1 (Step 1) Production of a carboxymethylated dextran sodium salt (1) 40 g of sodium hydroxide was added to and dis solved into 200 ml of purified water while cooling over 20 ice. Into the resultant solution was dissolved 10 g of dextran T110, (manufactured and sold by Extrasyntese, France), to thereby obtain a mixture. To the obtained mixture was added 50 g of monochloroacetic acid at room temperature to effect a reaction for 20 hours, to 25 thereby obtain a reaction mixture. The pH value of the obtained reaction mixture was adjusted to 8 with acetic acid. The reaction mixture having a pH value of 8 was poured into 1.5 liters of methanol, to thereby generate a precipitate. The generated precipitate was collected and dissolved in 200 ml of purified water, to thereby obtain a solution. The obtained solution was dialyzed against purified water using a dialysis membrane (cut off molecular weight: 12,000 to 14,000, manufactured and sold by Spectrum Medical Ind., Inc., U.S.A) at 4 °C
for two days, to thereby obtain a dialyzate. The obtained dialyzate was subjected to filtration using a membrane filter (pore size: 0.22 um), followed by lyophilization to thereby obtain compound (1) (11.5 g).
The degree of carboxymethylation of the obtained com-pound (1) per sugar residue was 0.6. The gel filtra-tion chromatograms of compound (1) are shown in Figs. 1 and 2. The chromatogram shown in Fig. 1 was obtained using an ultraviolet detector (wavelength: 214 nm).
The chromatogram shown in Fig. 2 was obtained using a differential refractometer as a detector. The molecu-lar weight of compound (1) was approximately 150,000, as measured by gel filtration using pullulan as a standard.
(Step 2) Production of 2'-Gly-paclitaxel (2) Fmoc-Gly (178 mg, 0.6 mmol), dimethylaminopyridine (73 mg, 0.6 mmol) and paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution.
To the obtained solution was added N,N'-diisopropylcar-bodiimide (76 mg, 0.6 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture.
The obtained reaction mixture was evaporated to dry-ness, to thereby obtain a residue. The obtained resi-due was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methylene chloride /
acetonitrile = 70/30), to thereby obtain 499 mg of 2'-Fmoc-Gly-paclitaxel. 420 mg of the obtained compound was dissolved in 10 ml of N,N-dimethylformamide, fol-lowed by adding thereto 2 ml of piperidine at room temperature, to thereby obtain a mixture. The obtained mixture was stirred for 5 minutes to effect a reaction for removing the Fmoc group, to thereby obtain a reac-tion mixture. The obtained reaction mixture was evapo-rated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 50 cm, eluent: aceto-nitrile / methylene chloride = 80/20) to thereby obtain 141 mg of compound (2).
1H-NMR (DMSO-d6): 81.01 (s, 3H, Me-17), 1.05 (s, 3H, Me-16), 1.52 (dd, 1H, J = 14.6, 9.2 Hz, H-14b), 1.51 (s, 3H, Me-19), 1.65 (t, 1H, J = 11.6 Hz, H-6b), 1.81 (dd, 1H, J = 15.5, 9.6 Hz, H-14a), 1.86 (s, 3H, Me-18), 2.11 (s, 3H, Ac-10), 2.23 (s, 3H, Ac-4), 2.32 (m, 1H, H-6a), 3.58 (d, 1H, J = 7.0 Hz, H-3), 3.96 -4.07 (m, 3H, GlyCH2, H-20), 4.10 (dd, 1H, J = 6.7, 10.7 Hz, H-7), 4.63 (s, 1H, OH-1), 4.90 (brs, 1H, OH-7), 4.91 (dd, 1H, J = 4.9 Hz, H-5), 5.43 (d, 1H, J = 7.0 Hz, H-2), 5.46 (d, 1H, J = 8.2 Hz, H-2'), 5.58 (t, 1H, J = 8.4 Hz, H-3'), 5.87 (t, 1H, J = 8.6 Hz, H-13), 6.30 (s, 1H, H-10), 7.19-8.00 (aromatic, 15H), 8.40 (brs, 2H, GlyNH2), 9.25 (d, 1H, J = 8.6 Hz, CONH-3') HRMS: m/z 911.3604 (M + H)+ . the molecular weight calculated for C49H55015N2 911.3602 (Step 3) Production of carboxymethylated dextran-2'-Gly-paclitaxel (3) 100 mg of carboxymethylated dextran sodium salt (1) obtained-in step 1 was dissolved in 2 ml of water.
To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 30 mg of 2'-Gly-paclitaxel (2) obtained in step 2, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 105 mg of compound (3) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (3) was calculated from the ultraviolet absorbance at 254 nm, and found to be 3.7 % by weight, based on the weight of compound (3). The gel filtration chromato-gram of compound (3) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 3.
The ultraviolet absorption spectrum of compound (3) is shown in Fig. 4.

(Step 4) Production of propanoyl-2'-Gly-paclitaxel (4) Propionic acid (7.4 mg, 0.1 mmol) was dissolved in 2 ml of N,N-dimethylformamide, to thereby obtain a solution. To the obtained solution were added 2'-Gly-5 paclitaxel (2) (45 mg, 0.05 mmol) obtained in step 2, 4-dimethylaminopyridine (12 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction 10 mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9365, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: methylene chlo-15 ride / acetonitrile = 70/30) to thereby obtain 30 mg of compound (4) (drug complex).
1H-NMR (DMSO-d6) . 81.01 (s, 3H, Me-17), 1.05 (s, 3H, Me-16), 1.06 (t, 3H, J = 7.5 Hz, Me-Pr), 1.52 (dd, 1H, J = 14.6, 9.2 Hz, H-14b), 1.51 (s, 3H, Me-19), 1.65 20 (t, 1H, J = 11.6 Hz, H-6b), 1.81 (dd, 1H, J = 15.5, 9.6 Hz, H-14a), 1.86 (s, 3H, Me-18), 2.11 (s, 3H, Ac-10), 2.23 (s, 3H, Ac-4), 2.32 (m, 1H, H-6a), 2.40 (q, 2H, J
- 7.5 Hz, CH2-Pr), 3.58 (d, 1H, J = 7.0 Hz, H-3), 3.96-4.07 (m, 3H, GlyCH2, H-20), 4.10 (dd, 1H, J = 6.7, 10.7 25 Hz, H-7), 4.63 (s, 1H, OH-1), 4.90 (brs, 1H, OH-7), 4.91 (dd, 1H, J = 4.9 Hz, H-5), 5.43 (d, 1H, J = 7.0 Hz, H-2), 5.46 (d, 1H, J = 8.2 Hz, H-2'), 5.58 (t, 1H, J = 8.4 Hz, H-3'), 5.87 (t, 1H, J = 8.6 Hz, H-13), 6.30 (s, 1H, H-10), 7.19-8.00 (aromatic, 15H), 8.40 (brs, 2H, GlyNH2), 9.25 (d, 1H, J = 8.6 Hz, CONH-3') (Step 5) Production of PEG-2'-Gly-paclitaxel (5) Carboxymethylated PEG (CM-PEG) was prepared from PEG [poly(ethylene glycol)methyl ether, Mw = 5,000, manufactured and sold by Aldrich, U.S.A] using ethyl monobromoacetate and tBuOK, according to the methods described in Journal of Controlled Release, 10, 145-154 (1989) and Polymer Bulletin, 18, 487-493 (1987). The prepared CM-PEG (500 mg, 0.1 mmol) was dissolved in 5 ml of N,N-dimethylformamide, to thereby obtain a solu-tion. To the obtained solution were added 2'-Gly-paclitaxel (2) (45 mg, 0.05 mmol) obtained in step 2, 4-dimethylaminopyridine (l2 mg, 0.1 mmol) and N,N-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed bY stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was dissolved into 2-propanol while heating, and the resultant solution was subjected to recrystallization, to thereby generate a precipitate. The generated precipitate was washed with cooled 2-propanol and ether successively, followed by drying under reduced pressure, to thereby obtain 150 mg of compound (5) (drug complex). The ultraviolet ab-sorption spectrum of compound (5) is shown in Fig. 5.
Example 2 (Step 1) Production of 2'-Ala-paclitaxel (6) Z-Ala (145 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methy-lene chloride / acetonitrile = 70/30), to thereby obtain 431 mg of 2'-Z-Ala-paclitaxel. 400 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 200 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The ob-tained solution was evaporated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatogra-phy (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 2.0 x 30 cm, eluent: methylene chlo-ride / methanol / acetonitrile = 95/5/5), to thereby obtain 231 mg of compound (6).
1H-NMR (DMSO-d6) . 61.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.14 (s, 3H, Me-Ala), 1.51 (s, 3H, Me-19), 1.61 (dd, 1H, J = 15.6, 9.2 Hz, H-14b), 1.64 (t, lH, J
- 12.8 Hz, H-6b), 1.81 (s, 3H, Me-18), 1.88 (dd, 1H, J
- 15.3, 9.5 Hz, H-14a), 2.11 (s, 3H, Ac-10), 2.27 (s, 3H, Ac-4), 2.33 (m, 1H, H-6a), 3.52 (q, 1H, J = 7.0 Hz, H-Ala), 3.60 (d, 1H, J = 7.3 Hz, H-3), 4.02 (d, 1H, J =
15.0 Hz, H-20), 4.03 (d, 1H, J = 15.0 Hz, H-20), 4.12 (ddd, 1H, J = 6.6, 6.6, 17.4 Hz, H-7), 4.66 (s, 1H, OH-1), 4.91 (d, lH, J = 6.6 Hz, OH-7), 4.92 (dd, 1H, J =
9.8 Hz, H-5), 5.35 (t, 1H, J = 8.6 Hz, H-2'), 5.43 (d, 1H, J = 7.0 Hz, H-2), 5.64 (t, 1H, J-8.6 Hz, H-3'), 5.87 (t, 1H, J=9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.17 (d, 1H, J=8.9 Hz, CONH-3') HRMS: m/z 925.3797 (M + H)+ . the molecular weight calculated for C50H57015N2 925.3759 (Step 2) Production of carboxymethylated dextran-2'-Ala-paclitaxel (7) 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 30 mg of 2'-Ala-paclitaxel (6) obtained in step 1, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1;2-dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 105 mg of compound (7) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound 5 (7) was calculated from the ultraviolet absorbance at 254 nm, and found to be 1.7 o by weight, based on the weight of compound (7). The gel filtration chromato-gram of compound (7) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 6.
10 The ultraviolet absorption spectrum of compound (7) is shown in Fig. 7.
(Step 3) Production of propanoyl-2'-Ala-paclitaxel (8) Propionic acid (7.4 mg, 0.1 mmol) was dissolved in 15 2 ml of N,N-dimethylformamide, to thereby obtain a .
solution. To the obtained solution were added 2'-Ala-paclitaxel (6) (45 mg, 0.05 mmol) obtained in step 1, 4-dimethylaminopyridine (l2 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed 20 by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, 25 Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: methylene chlo-ride / acetonitrile = 70/30) to thereby obtain 32 mg of compound (8) (drug complex).
1H-NMR (DMSO-d6) . 81.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.06 (t, 3H, J = 7.5 Hz, Me-Pr), 1.14 (s, 3H, Me-Ala), 1.51 (s, 3H, Me-19), 1.61 (dd, 1H, J =
15.6, 9.2 Hz, H-14b), 1.64 (t, 1H, J = 12.8 Hz, H-6b), 1.81 (s, 3H, Me-18), 1.88 (dd, 1H, J = 15.3, 9.5 Hz, H-14a), 2.11 (s, 3H, Ac-10), 2.27 (s, 3H, Ac-4), 2.33 (m, 1H, H-6a), 2.40 (q, 2H, J = 7.5 Hz, CH2-Pr), 3.52 (q, 1H, J = 7.0 Hz, H-Ala), 3.60 (d, 1H, J = 7.3 Hz, H-3), 4.02 (d, 1H, J = 15.0 Hz, H-20), 4.03 (d, 1H, J = 15.0 Hz, H-20), 4.12 (ddd, 1H, J = 6.6, 6.6, 17.4 Hz, H-7), 4.66 (s, 1H, OH-1), 4.91 (d, 1H, J = 6.6 Hz, OH-7), 4.92 (dd, 1H, J = 9.8 Hz, H-5), 5.35 (d, 1H, J = 8.6 Hz, H-2'), 5.43 (d, 1H, J = 7.0 Hz, H-2), 5.64 (t, lH, J = 8.6 Hz, H-3'), 5.87 (t, 1H, J = 9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.17 (d, 1H, J = 8.9 Hz, CONH-3') (Step 4) Production of PEG-2'-Ala-paclitaxel (9) CM-PEG (500 mg, 0.1 mmol) obtained in step 5 of Example 1 was dissolved in 5 ml of N,N-dimethylforma-mide, to thereby obtain a solution. To the obtained solution were added 2'-Ala-paclitaxel (6) (45 mg, 0.05 mmol) obtained in step 1, 4-dimethylaminopyridine (12 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was dissolved into 2-propanol while heating, and the re-sultant solution was subjected to recrystallization, to thereby generate a precipitate. The generated pre-cipitate was washed with cooled 2-propanol and ether successively, followed by drying under reduced pres-sure, to thereby obtain 160 mg of compound (9) (drug complex). The ultraviolet absorbance spectrum of compound (9) is shown in Fig. 8.
Example 3 (Step 1) Production of 2'-Leu-paclitaxel (10) Z-Leu (172 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methy-lene chloride / acetonitrile = 70/30), to thereby obtain 454 mg of 2'-Z-Leu-paclitaxel. 400 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 200 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The ob-tamed solution was evaporated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatogra-phy (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methylene chlo-ride / methanol / acetonitrile = 95/5/5), to thereby obtain 289 mg of compound (10).
1H-NMR (DMSO-d6) . s0.66 (a, 3H, Me-Leu), 0.70 (a, 3H, Me-Leu), 1.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.26 (ddd, 1H, J = 6.4, 8.5, 13.4 Hz, H-Leu), 1.36 (ddd, 1H, J = 5.8, 7.6, 13.4 Hz, H-Leu), 1.51 (s, 3H, Me-19), 1.56 (dd, 1H, J = 15.3, 9.0 Hz, H-14b), 1.64 (m, 1H, H-6b), 1.67 (m, 1H, H-Leu), 1.79 (s, 3H Me-18), 1.84 (dd, 1H, J = 15.3, 9.5 Hz, H-14a), 2.10 (s, 3H, Ac-10), 2.25 (s, 3H, Ac-4), 2.33 (ddd, 1H, J =
14.7, 9.5, 6.4 Hz, H-6a), 3.38 (dd, 1H, J = 8.6, 5.8 Hz, H-Leu), 3.59 (d, 1H, J = 7.0 Hz, H-3), 4.01 (d, 1H, J = 16.8 Hz, H-20), 4.03 (d, 1H, J = 16.8 Hz, H-20), 4.12 (ddd, 1H, J = 6.9, 6.9, 11.0 Hz, H-7), 4.64 (s, 1H, OH-1), 4.90 (d, 1H, J = 7.0 Hz, OH-7), 4.92 (d, 1H, J = 10.1 Hz, H-5), 5.34 (d, 1H, J = 9.2 Hz, H-2'), 5.42 (d, 1H, J = 7.0 Hz, H-2), 5.62 (t, 1H, J = 9.0 Hz, H-3'), 5.86 (t, 1H, J = 9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.16 (d, 1H, J = 8.9 Hz, CONH-3') HRMS . m/z 967.4321 (M + H)+ . the molecular weight calculated for C53H63~15N2 967.4228 (Step 2) Production of carboxymethylated dextran-2'-Leu-paclitaxel (11) 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 30 mg of 2'-Leu-paclitaxel (10) obtained in step 2, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-5 dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-10 cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 106 15 mg of compound (11) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (11) was calculated from the ultraviolet absorbance at 254 nm, and found to be 1.7 o by weight, based on the 20 weight of compound (11). The gel filtration chromato-gram of compound (11) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 9.
The ultraviolet absorption spectrum of compound (11) is shown in Fig. 10.

(Step 3) Production of propanoyl-2'-Leu-paclitaxel (12) Propionic acid (7.4 mg, 0.1 mmol) was dissolved in 2 ml of N,N-dimethylformamide, to thereby obtain a solution. To the obtained solution were added 2'-Leu-paclitaxel (10) (45 mg, 0.05 mmol) obtained in step 1, 4-dimethylaminopyridine (12 mg, 0.1 mmol) and N, N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: methylene chlo-ride / acetonitrile = 70/30), to thereby obtain 34 mg of compound (12) (drug complex).
1H-NMR (DMSO-d6) . 80.66 (d, 3H, Me-Leu), 0.70 (d, 3H, Me-Leu), 1.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.06 (t, 3H, J = 7.5 Hz, Me-Pr), 1.26 (ddd, 1H, J =
6.4, 8.5, 13.4 Hz, H-Leu), 1.36 (ddd, 1H, J = 5.8, 7.6, 13.4 Hz, H-Leu), 1.51 (s, 3H, Me-19), 1.56 (dd, 1H, J =
15.3, 9.0 Hz, H-14b), 1.64 (m, 1H, H-6b), 1.67 (m, 1H, H-Leu), 1.79 (s, 3H, Me-18), 1.84 (dd, 1H, J = 15.3, 9.5 Hz, H-14a), 2.10 (s, 3H, Ac-10), 2.25 (s, 3H, Ac-4), 2.33 (ddd, 1H, J = 14.7, 9.5, 6.4 Hz, H-6a), 2.40 (q, 2H, J = 7.5 Hz, CH2-Pr), 3.38 (dd, 1H, J = 8.6, 5.8 Hz, H-Leu), 3.59 (d, 1H, J = 7.0 Hz, H-3), 4.01 (d, 1H, J = 16.8 Hz, H-20), 4.03 (d, 1H, J = 16.8 Hz, H-20), 4.12 (ddd, 1H, J = 6.9, 6.9, 11.0 Hz, H-7), 4.64 (s, 1H, OH-1), 4.90 (d, 1H, J = 7.0 Hz, OH-7), 4.92 (d, 1H, J = 10.1 Hz, H-5), 5.34 (d, 1H, J = 9.2 Hz, H-2'), 5.42 (d, 1H, J = 7.0 Hz, H-2), 5.62 (t, 1H, J = 9.0 Hz, H-3'), 5.86 (t, 1H, J = 9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.16 (d, 1H, J = 8.9 Hz, CONH-3') (Step 4) Production of PEG-2'-Leu-paclitaxel (13) CM-PEG (500 mg, 0.1 mmol) obtained in step 5 of Example 1 was dissolved in 5 ml of N,N-dimethylforma-mide, to thereby obtain a solution. To the obtained solution were added 2'-Leu-paclitaxel (10) (45 mg, 0.05 mmol) obtained in step l, 4=dimethylaminopyridine (12 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was dissolved into 2-propanol while heating, and the re-sultant solution was subjected to recrystallization, to thereby generate a precipitate. The generated pre-cipitate was washed with cooled 2-propanol and ether successively, followed by drying under reduced pres-sure, to thereby obtain 145 mg of compound (13) (drug complex). The ultraviolet absorption spectrum of compound (13) is shown in Fig. 11.
Example 4 (Step 1) Production of 2'-Ile-paclitaxel (14) Fmoc-Ile (212 mg, 0.6 mmol), dimethylaminopyridine (73 mg, 0.6 mmol) and paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution.
To the obtained solution was added N,N'-diisopropylcar-bodiimide (76 mg, 0.6 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture.
The obtained reaction mixture was evaporated to dry-ness, to thereby obtain a residue. The obtained resi-due was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 2.0 x 30 cm, eluent: methylene chloride /
acetonitrile = 70/30), to thereby obtain 552 mg of 2'-Fmoc-Ile-paclitaxel. 470 mg of the obtained compound was dissolved in 10 ml of DMF, followed by adding thereto 2 ml of piperidine at room temperature, to thereby obtain a mixture. The obtained mixture was stirred for 5 minutes to effect a reaction for removing Fmoc group, thereby obtaining a reaction mixture. The obtained reaction mixture was evaporated to dryness under reduced pressure, to thereby obtain a residue.
The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methy-lene chloride / methanol / acetonitrile = 95/5/5) to thereby obtain 353 mg of compound (14).
1H-NMR (DMSO-d6) . 80.62 (t, 3H, J = 7.5 Hz, Me-Ile), 0.81 (d, 3H, J = 6.7 Hz, Me-Ile), 1.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.07 (ddd, 1H, J = 14.4, 7.3, 4.9 Hz, H-Ile), 1.32 (ddd, 1H, J = 13.4, 7.6, 4.6 Hz, H-Ile), 1.51 (s, 3H, Me-19), 1.56 (dd, 1H, J =
15.3, 9.2 Hz, H-14b), 1.56--1.61 (m, 1H, H-Ile), 1.64 (dd, 1H, J = 13.7, 3.1 Hz, H-6b), 1.79 (s, 3H, Me-18), 1~87 (dd, 1H, J = 15.3, 9.8 Hz, H-14a), 2.10 (s, 3H, Ac-10), 2.29 (s, 3H, Ac-4), 2.33 (ddd, 1H, J = 14.4, 9.6, 6.4 Hz, H-6a), 3.60 (d, 1H, J = 7.3 Hz, H-3), 3.60-3.67 (m, 1H, H-Ile), 4.02 (d, 1H, J = 16.6 Hz, H-20), 4.03 (d, 1H, J = 16.6 Hz, H-20), 4.12 (ddd, 1H, J
- 10.8, 6.7, 6.7 Hz, H-7), 4.64 (s, 1H, OH-1), 4.90 (d, 1H, J = 7.0, OH-7), 4.92 (d, 1H, J = 9.8 Hz, H-5), 5.37 (d, 1H, J = 8.9 Hz, H-2'), 5.43 (d, 1H, J = 7.3 Hz, H-2), 5.64 (t, 1H, J = 8.7 Hz, H-3'), 5.85 (dt, 1H, J =
0.9, 9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.15 (d, 1H, J = 9.2 Hz, CONH-3') HRMS: m/z 967.4234 (M + H)+ . the molecular weight calculated for C53H63015N2 967~4228 (Step 2) Production of carboxymethylated dextran-2'-10 Ile-paclitaxel (15) 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the 15 resultant mixture were added 0.5 ml of a solution containing 30 mg of 2'-Ile-paclitaxel (14) obtained in step 2, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-20 dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-25 cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 105 mg of compound (15) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (15) was calculated from the ultraviolet absorbance at 254 nm, and found to be 1.6 % by weight, based on the weight of compound (15). The gel filtration chromato-gram of compound (15) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 12.
The ultraviolet absorption spectrum of compound (15) is shown in Fig. 13.
(3tep 3) Production of propanoyl-2'-Ile-paclitaxel (16) Propionic acid (7.4 mg; 0.1 mmol) was dissolved in 2 ml of N,N-dimethylformamide, to thereby obtain a solution. To the obtained solution were added 2'-Ile-paclitaxel (14) (45 mg, 0.05 mmol) obtained in step 1, 4-dimethylaminopyridine (12 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: methylene chlo-ride / acetonitrile = 70/30) to thereby obtain 28 mg of compound (16) (drug complex).
1H-NMR (DMSO-d6) . 60.62 (t, 3H, J = 7.5 Hz, Me-Ile), 0.81 (d, 3H, J = 6.7 Hz, Me-Ile), 1.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.06 (t, 3H, J = 7.5 Hz, Me-Pr), 1.07 (ddd, 1H, J = 14.4, 7.3, 4.9 Hz, H-Ile), 1.32 (ddd, 1H, J = 13.4, 7.6, 4.6 Hz, H-Ile), 1.51 (s, 3H, Me-19), 1.56 (dd, 1H, J = 15.3, 9.2 Hz, H-14b), 1.56-1.61 (m, 1H, H-Ile), 1.64 (dd, 1H, J = 13.7, 3.1 Hz, H-6b), 1.79 (s, 3H, Me-18), 1.87 (dd, 1H, J = 15.3, 9.8 Hz, H-14a), 2.10 (s, 3H, Ac-10), 2.29 (s, 3H, Ac-4), 2.33 (ddd, 1H, J = 14.4, 9.6, 6.4 Hz, H-6a), 2.40 (q, 2H, J = 7.5 Hz, CH2-Pr), 3.60 (d, 1H, J = 7.3 Hz, H-3), 3.60-3.67 (m, 1H, H-Ile), 4.02 (d, 1H, J = 16.6 Hz, H-20), 4.03 (d, 1H, J = 16.6 Hz, H-20), 4.12 (ddd, 1H, J = 10.8, 6.7, 6.7 Hz, H-7), 4.64 (s, 1H, OH-1), 4.90 (d, 1H, J = 7.0 Hz, OH-7), 4.92 (d, 1H, J = 9.8 Hz, H-5), 5.37 (d, 1H, J = 8.9 Hz, H-2'), 5.43 (d, 1H, J = 7.3 Hz, H-2), 5.64 (t, 1H, J = 8.7 Hz, H-3'), 5.85 (dt, 1H, J = 0.9, 9.2 Hz, H-13), 6.30 (s, 1H, H-10), 7.20-8.00 (aromatic, 15H), 9.15 (d, 1H, J = 9.2 Hz, CONH-3') (Step 4) Production of PEG-2'-Ile-paclitaxel (17) CM-PEG (500 mg, 0.1 mmol) obtained in step 5 of Example 1 was dissolved in 5 ml of N,N-dimethylforma-mide, to thereby obtain a solution. To the obtained solution were added 2'-Ile-paclitaxel (14) (45 mg, 0.05 mmol) obtained in step 1, 4-dimethylaminopyridine (12 mg, 0.1 mmol) and N,N'-diisopropylcarbodiimide (12.6 mg, 0.1 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was dissolved into 2-propanol while heating, and the re-sultant solution was subjected to recrystallization, to thereby generate a precipitate. The generated pre-cipitate was washed with cooled 2-propanol and ether successively, followed by drying under reduced pres-sure, to thereby obtain 125 mg of compound (17) (drug complex). The ultraviolet absorption spectrum of compound (17) is shown in Fig. 14.
Example 5 (Step 1) Production of 2'-Phe-paclitaxel (18) Z-Phe (194 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, methylene chloride / acetonitrile =
70/30), to thereby obtain 428 mg of 2'-Z-Phe-paclitax-el. 400 mg of the obtained compound was dissolved in ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 200 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an at-mosphere of hydrogen, to thereby obtain a reaction 20 mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evaporated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column: 4.0 x 30 cm, eluent: methylene chloride / methanol / acetonitrile =
95/5/5), to thereby obtain 269 mg of compound (18).
5 1H-NMR (DMSO-d6) . 81.02 (s, 3H, Me-17), 1.05 (s, 3H, Me-16), 1.52 (s, 3H, Me-19), 1.64 (dd, 1H, J =
15.6, 9.2 Hz, H-14b), 1.66 (dd, 1H, J = 14.4, 11.3 Hz, H-6b), 1.85 (s, 3H, Me-18), 1.93 (dd, 1H, J = 15.3, 9.5 Hz, H-14a), 2.11 (s, 3H, Ac-10), 2.30 (s, 3H, Ac-4), 10 2.32 (ddd, 1H, J = 14.7, 9.6, 6.6 Hz, H-6a), 2.99 (dd, 1H, 14.5, 6.9 Hz, PheCH2), 3.13 (dd, 1H, 14.4, 5.2 Hz, PheCH2), 3.61 (d, 1H, J = 7.3 Hz, H-3), 4.10 (dd, 1H, J
- 11.0, 6.7 Hz, H-7), 4.52 (t, 1H, J = 5.8 Hz, PheCH), 4.68 (s, 1H, OH-1), 4.89 (d, 1H, J = 7.0 Hz, OH-7), 15 4.92 (d, 1H, J = 9.8 Hz, H-5), 5.47 (d, 1H, J = 7.3 Hz, H-2'), 5.50 (d, 1H, J = 7.3 Hz, H-2), 5.78 (t, 1H,.J =
8.2 Hz, H-3'), 5.94 (t, 1H, J = 8.9 Hz, H-13), 6.30 (s, 1H, H-10), 7.00-8.10 (m, 20H, aromatic), 8.49 (brs, 2H, NH2) 9.26 (d, 1H, J = 8.9 Hz, CONH-3') 20 HRMS: m/z 1001.4076 (M + H)+ . the molecular weight calculated for C56H61015N2 1001.4072 (Step 2) Production of carboxymethylated dextran-2'-Phe-paclitaxel (19) 25 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 30 mg of 2'-Phe-paclitaxel (18) obtained in step 1, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 106 mg of compound (19) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (19) was calculated from the ultraviolet absorbance at 254 nm, and found to be 4.7 % by weight, based on the weight of compound (19). The gel filtration chromato-gram of compound (19) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 15.
The ultraviolet absorption spectrum of compound (19) is shown in Fig. 16.
Example 6 (Step 1) Production of 2'-Phe-Gly-paclitaxel hydrochlo-ride (20) Phe-Gly (manufactured and sold by PEPTIDE INSTI-TUTE INC., Japan, 1.1 g, 5 mmol) was dissolved in a mixture of 2 ml of H20, 2 ml of 2-propanol and 1.5 ml of diethylamine, to thereby obtain a solution. To the obtained solution was portionwise added trityl chloride (1.8 g, 6.5 mmol), followed by stirring for one hour.
To the resultant reaction mixture was added H20, to thereby generate a precipitate. The generated pre-cipitate was collected, washed with water and then dis-solved into 5 ml of acetic acid, to thereby obtain an acidic solution. The obtained acidic solution was evaporated to dryness under reduced pressure, to there-by obtain 1.5 g of Trt-Phe-Gly.
The above-obtained Trt-Phe-Gly (604 mg, 1.3 mmol), dimethylaminopyridine (158 mg, 1.3 mmol) and paclitaxel (manufactured and sold by DABUR, India, 853 mg, 1.0 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (164 mg, 1.3 mmol), followed by stirring overnight at room tempera-ture, to thereby obtain a reaction mixture. The ob-tained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manu-factured and sold by E. Merck, Darmstadt, Germany, Column . 4.0 x 30 cm, eluent . methylene chloride /
acetonitrile = 80/20), to thereby obtain 983 mg of 2'-Trt-Phe-Gly-paclitaxel. 800 mg of the above-obtained compound was treated with 10 ml of 90 % acetic acid to effect a reaction for removing N-trityl group. The resultant compound was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 30 cm, eluent .
methylene chloride / methanol / acetonitrile = 95/5/5), and subsequently converted to a corresponding hydro-chloride thereof, to thereby obtain 490 mg of compound (20).
1H-NMR (DMSO-d6) . 81.01 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.42 (dd, 1H, J = 15.5, 9.1 Hz, H-14b), 1.50 (s, 3H, Me-19), 1.63 (t, 1H, J = 12.2 Hz, H-6b), 1.75 (dd, 1H, J = 12.3, 9.5 Hz, H-14a), 1.81 (s, 3H, Me-18), 2.12 (s, 3H, Ac-10), 2.23 (s, 3H, Ac-4), 2.29 (ddd, 1H, J = 14.4, 9.2, 7.0 Hz, H-6a), 2.90 (dd, 1H, 14.2, 7.8 Hz, PheCH2), 3.08 (dd, 1H, 14.4, 5.2 Hz, PheCH2), 3.56 (d, 1H, J = 7.0 Hz, H-3), 4.05-4.10 (m, 2H, H-7, PheCH), 4.15 (dd, 1H, J = 18.0, 5.8 Hz, Gly), 4.61 (brs, 1H, OH-1), 4.90 (brs, 1H, OH-7), 4.90 (d, 1H, J = 5.3 Hz, H-5), 5.38 (d, 1H, J = 8.9 Hz, H-2'), 5.41 (d, 1H, J = 7.0 Hz, H-2), 5.53 (t, 1H, J = 8.6 Hz, H-3'), 5.83 (t, 1H, J = 8.8 Hz, H-13), 6.29 (s, 1H, H-10), 7.16-8.00 (m, 20H, aromatic), 8.15 (brs, 2H, NH2) 9.02 (t, 1H, J = 5.8 Hz, Gly-NH), 9.29 (d, 1H, J = 8.9 Hz, CONH-3') HRMS: m/z 1058.4241 (M + H)+ . the molecular weight calculated for C58H64016N3 1058.4287 (Step 2) Production of carboxymethylated dextran-2'-Phe-Gly-paclitaxel (21) 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 22 mg of 2'-Phe-Gly-paclitaxel (20) obtained in step 1, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solu-tion containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-dimethylforma-mide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The 5 obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The gener-ated precipitate was collected and dissolved in 10 ml of purified water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a pre-10 cipitate. The generated precipitate was washed with acetone and ether successively, to thereby obtain 108 mg of compound (21) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound 15 (21) was calculated from the ultraviolet absorbance at 254 nm, and found to be 3.3 % by weight, based on the weight of compound (21). The gel filtration chromato-gram of compound (21) was obtained using an ultravio-let detector (wavelength: 227 nm), and is shown in Fig.
20 17. The ultraviolet absorption spectrum of compound (21) is shown in Fig. 18.
Example 7 (Step 1) Production of 2'-Gly-Phe-paclitaxel hydrochlo-25 ride (22) Production of compound (22) was conducted in substantially the same manner as in step 1 of Example 6. That is, Gly-Phe (manufactured and sold by PEPTIDE
INSTITUTE INC., Japan, 1.1 g, 5 mmol) was dissolved in a mixture of 2 ml of H20, 2 ml of 2-propanol and 1.5 ml of diethylamine, to obtain a solution. To the obtained solution was portionwise added trityl chloride (1.8 g, 6.5 mmol), followed by stirring for one hour. To the resultant reaction mixture was added H20, to thereby generate a precipitate. The generated precipitate was collected, washed with water and then dissolved into 5 ml of acetic acid, to thereby obtain an acidic solu-tion. The obtained acidic solution was evaporated to dryness under reduced pressure, to thereby obtain 1.5 g of Trt-Gly-Phe.
The above-obtained Trt-Gly-Phe (604 mg, 1.3 mmol), dimethylaminopyridine (158 mg, 1.3 mmol) and paclitaxel (manufactured and sold by DABUR, India, 853 mg, 1.0 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a mixture. To the obtained mixture was added N,N'-diisopropylcarbodiimide (164 mg, 1.3 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reac-tion mixture was evaporated to dryness to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No.
9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 30 cm, eluent . methylene chloride / acetonitrile =
80/20), to thereby obtain 968 mg of 2'-Trt-Gly-Phe-paclitaxel. 800 mg of the above-obtained compound was treated with 10 ml of 90 % acetic acid to effect a reaction for removing N-trityl group. The resultant compound was purified by silica gel column chromatogra-phy (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 30 cm, eluent . methylene chloride / methanol / acetonitrile = 95/5/5), and subsequently converted to a corresponding hydrochloride thereof, to thereby obtain 520 mg of compound (22).
1H-NMR (DMSO-d6) . 81.02 (s, 3H, Me-17), 1.05 (s, 3H, Me-16), 1.52 (s, 3H, Me-19), 1.66 (dd, 1H, J =
15.0, 9.5 Hz, H-14b), 1.66 (t, 1H, J = 10.7 Hz, H-6b), 1.82 (s, 3H, Me-18), 1.94 (dd, 1H, J = 15.2, 9.7 Hz, H-14a), 2.11 (s, 3H, Ac-10), 2.30 (br, 1H, H-6a), 2.33 (s, 3H, Ac-4), 2.76 (dd, 1H, 14.1, 9.5 Hz, PheCH2), 2.97 (dd, 1H, 14.0, 3.6 Hz, PheCH2), 3.46 (d, 1H, J =
16.2, Gly), 3.51 (d, 1H, J = 16.5, Gly), 3.61 (d, 1H, J
- 7.3 Hz, H-3), 4.03 (d, 1H, J = 8.9 Hz, H-20), 4.05 (d, 1H, J = 8.9 Hz, H-20), 4.10 (dd, 1H, J = 10.5, 6.9 Hz, H-7), 4.71 (brs, 1H, OH-1), 4.79 (ddd, 1H, J = 9.0, 9.0, 3.7 Hz, PheCH), 4.92 (brs, 1H, OH-7), 4.93 (d, 1H, J = 10.4 Hz, H-5), 5.40 (d, 1H, J = 7.6 Hz, H-2'), 5.44 (d, 1H, J = 7.3 Hz, H-2), 5.79 (dd, 1H, J = 8.6, 7.9 Hz, H-3'), 5.93 (t, 1H, J = 8.9 Hz, H-13), 6.29 (s, 1H, H-10), 6.97-8.02 (m, 20H, aromatic), 7.97 (brs, 2H, GlyNH2), 8.88 (d, 1H, J = 8.2 Hz, Phe-NH), 9.30 (d, 1H, J = 9.2 Hz, CONH-3') HRMS: m/z 1058.4333 (M + H)+ . the molecular weight calculated for C58H64016N3 1058.4287 (Step 2) Production of carboxymethylated dextran-2'-Gly-Phe-paclitaxel (23) 100 mg of carboxymethylated dextran sodium salt (1) obtained in Example 1 was dissolved in 2 ml of water. To the resultant solution was added 2 ml of N, N-dimethylformamide while cooling over ice. To the resultant mixture were added 0.5 ml of a solution containing 15 mg of 2'-Gly-Phe-paclitaxel (22) obtained in step l, which is dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 0.5 ml of a solution containing 100 mg of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-dimethylformamide, followed by stirring at room temperature for two hours, to thereby obtain a reaction mixture. The obtained reaction mixture was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated pre-cipitate was collected and dissolved in 10 ml of puri-fied water. The resultant solution was poured into 100 ml of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 101 mg of compound (23) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (23) was calculated from the ultraviolet absorbance at 254 nm, and found to be 4.7 o by weight, based on the weight of compound (23). The gel filtration chromato-gram of compound (23) was obtained using an ultraviolet detector (wavelength: 227 nm), and is shown in Fig. 19.
The ultraviolet absorption spectrum of compound (23) is shown in Fig. 20.

Example 8 (1) Production of 21-propanoylisoleucyl-dexamethasone (24) Z-Ile (172 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) 10 and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, 15 Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
ethyl acetate = 50/30), to thereby obtain 62 mg of 21-Z-Ile-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a 20 mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby 25 obtaining a solution. The obtained solution was evaporated to dryness under reduced pressure, to there-by obtain a residue. The obtained residue was dis-solved in DMF, to thereby obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol) and propionic acid (37 mg, 0.5 mmol), fol-lowed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reac-tion mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No.
9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, chloroform /
ethyl acetate = 50/25), to thereby obtain 50 mg of compound (24) (drug complex).
1H-NMR (DMSO-d6) . 80.63 (s, 3H, J = 7.5 Hz), 0.76 (d, 3H, 7.5 Hz), 0.82 (d, 3H, J = 6.7 Hz), 0.87 (s, 3H), 1.07 (m, 2H), 1.10 (t, 3H, J = 7.5 Hz), 1.30-1.50 (m, 3H), 1.49 (s, 3H), 1.55-1.62 (m, 2H), 1.78 (m, 1H), 2.11 (m, 2H), 2.32 (m, 2H), 2.35 (q, 2H, J = 7.5 Hz), 2.60 (m, 1H), 2.94 (m, 1H), 3.60-3.68 (m, 1H), 4.16 (m, 1H), 4.68 (m, 1H), 4.68 (d, 1H, J = 17.2 Hz), 5.01 (d, 1H, J = 17.2 Hz), 5.16 (brs, 1H), 6.01 (s, 1H), 6.23 (d, 1H, J = 10.2 Hz), 7.30 (d, 1H, J = 10.2 Hz), 9.00 (d, 1H, J = 7.0 Hz) (2) Production of PEG-isoleucyl-21-dexamethasone (25) Z-Ile (172 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: chloroform /
ethyl acetate = 50/30), to thereby obtain 65 mg of 21-Z-Ile-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evapo-rated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in DMF, to thereby obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol) and the CM-PEG (2,500 mg, 0.5 mmol) obtained in step 5 of Example 1, followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was washed with 2-propanol and ether successively, followed by. drying under reduced pressure, to thereby obtain 1,000 mg of compound (25) (drug complex). The ultra-violet absorption spectrum of compound (25) is shown in Fig. 21.
(3) Production of 21-propanoylglycyl-dexamethasone (26) Z-Gly (135 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
methanol = 15/1), to thereby obtain 68 mg of 21-Z-Gly-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evapo-rated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in DMF, to thereby obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol) and propionic acid (37 mg, 0.5 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /

methanol = 17/1), to thereby obtain 30 mg of compound (26) (drug complex).
1H-NMR (DMSO-d6) . 80.74 (d, 3H, 7.5 Hz), 0.88 (d, 3H), 1.04 (t, 3H, J = 7.5 Hz), 1.07 (m, 2H), 1.30-1.50 (m, 3H), 1.52 (s, 3H), 1.60 (m, 2H), 1.78 (m, 1H), 2.14 (m, 2H), 2.32 (m, 2H), 2.37 (q, 2H, J = 7.5 Hz), 2.62 (m, 1H), 2.94 (m, 1H), 3.96-4.06 (m, 2H), 4.16 (m, 1H), 4.68 (m, 1H), 4.82 (d, 1H, J = 17.4 Hz), 4.98 (brs, 1H), 5.03 (d, 1H, J = 17.4 Hz), 6.02 (s, 1H), 6.24 (dd, 1H, J = 10.3, 1.7 Hz), 7.29 (d, 1H, J = 10.2 Hz), 9.02 (d, 2H, J = 7.0 Hz) (4) Production of PEG-glycyl-21-dexamethasone (27) Z-Gly (135 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel: Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent: chloroform /
methanol - 15/1) to thereby obtain 65 mg of 21-Z-Gly-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evapo-rated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in DMF, to thereby obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol) and the CM-PEG (2,500 mg, 0.5 mmol) obtained in step 1 of Example 5, followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was washed with 2-propanol and ether successively, followed by drying under reduced pressure, to thereby obtain 700 mg of compound (27) (drug complex). The ultraviolet absorption spectrum of compound (27) is shown in Fig.
22.

(5) Production of 21-propanoylalanyl-dexamethasone (28) Z-Ala (145 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
methanol = 20/1), to thereby obtain 70 mg of 21-Z-Ala-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evapo-rated to dryness under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in DMF, thereby to obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol) and propionic acid (37 mg, 0.5 mmol), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
methanol = 40/3), to thereby obtain 55 mg of compound (28) (drug complex).
1H-NMR (DMSO-d6) . 80.76 (d, 3H, 7.5 Hz), 0.89 (d, 3H), 1.06 (t, 3H, J = 7.5 Hz), 1.07 (m, 2H), 1.14 (s, 3H), 1.30-1.50 (m, 3H), 1.50 (s, 3H), 1.60 (m, 2H), 1.78 (m, 1H), 2.14 (m, 2H), 2.32 (m, 2H), 2.40 (q, 2H, J = 7.5 Hz), 2.60 (m, 1H), 2.94 (m, 1H), 3.50 (q, 1H, J
- 7.0 Hz), 4.16 (m, 1H), 4.68 (m, 1H), 4.78 (d, 1H, J =
17.0 Hz), 4.98 (brs, 1H), 5.02 (d, 1H, J = 17.0 Hz), 6.02 (s, 1H), 6.24 (dd, 1H, J = 10.3, 1.7 Hz), 7.29 (d, 1H, J = 10.2 Hz), 8.84 (d, 2H, J = 7.0 Hz) (6) Production of PEG-alanyl-21-dexamethasone (29) Z-Ala (145 mg, 0.65 mmol), dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to there-by obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
methanol = 20/1), to thereby obtain 68 mg of 21-Z-Ala-dexamethasone. 50 mg of the obtained compound was dissolved in 20 ml of dioxane, to thereby obtain a mixture. To the obtained mixture was added 50 mg of a palladium-carbon catalyst, followed by stirring for 4 hours in an atmosphere of hydrogen, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration to remove the catalyst, thereby obtaining a solution. The obtained solution was evapo-rated to dryness under reduced pressure to thereby obtain a residue. The obtained residue was dissolved in DMF, to thereby obtain a solution. To the obtained solution were added 4-dimethylaminopyridine (61 mg, 0.5 mmol), N,N'-diisopropylcarbodiimide (63 mg, 0.5 mmol), and the CM-PEG (2,500 mg, 0.5 mmol) obtained in step 5 of Example 1, followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was washed with 2-propanol and ether successively, followed by drying under reduced pressure, to thereby obtain 1,400 mg of compound (29) (drug complex). The ultra-violet absorption spectrum of compound (29) is shown in Fig. 23.
(7) Production of 21-propanoyl-dexamethasone (30) Propionic acid (48 mg, 0.65 mmol), dimethylamino-pyridine (79 mg, 0.65 mmol) and dexamethasone (manufac-tured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No.
9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloro-form / methanol = 7/1), to thereby obtain 50 mg of compound (30).
1H-NMR (DMSO-d6) . 80.79 (d, 3H, 7.2 Hz), 0.89 (d, 3H), 1.07 (t, 3H, J = 7.5 Hz), 1.07 (m, 1H), 1.30-1.50 (m, 3H), 1.49 (s, 3H), 1.60 (m, 2H), 1.78 (m, 1H), 2.14 (m, 2H), 2.32 (m, 2H), 2.37 (q, 2H, J = 7.5 Hz), 2.62 (m, 1H), 2.94 (m, 1H), 4.14 (m, 1H), 4.80 (d, 1H, J = 17.4 Hz), 5.03 (d, 1H, J = 17.4 Hz), 5.16 (brs, 1H), 5.40 (m, 1H), 6.01 (s, 1H), 6.23 (d, 1H, J = 9.9 Hz), 7.30 (d, 1H, J = 10.2 Hz) (8) Production of PEG-21-dexamethasone (31) CM-PEG (2,500 mg, 0.5 mmol) obtained in step 5 of Example 1, dimethylaminopyridine (79 mg, 0.65 mmol) and dexamethasone (manufactured and sold by Wako Pure Chemical Industries, Ltd., Japan, 196 mg, 0.5 mmol) were dissolved in 20 ml of DMF, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbodiimide (82 mg, 0.65 mmol) and stirred overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was collected and washed with 2-propanol and ether successively, followed by drying under reduced pressure, to thereby obtain 1,000 mg of compound (31). The ultraviolet absorption spectrum of compound (31) is shown in Fig. 24.
Reference Example 1 (Production of Trt-Gly-Gly-Phe-Gly) (1) Synthesis of Phe-Gly-OBn Phe-Gly~H20 (manufactured and sold by Kokusan Chemical Works Ltd., Japan, 25 g, 104 mmol) was dis-solved in a mixture of para-toluenesulfonic acid mono-hydrate (19.8 g, 104 mmol), 25 ml of benzyl alcohol and 200 ml of toluene, to thereby obtain a mixture. The obtained mixture was refluxed for 5 hours by means of a Dean-Stark apparatus, to thereby obtain a reaction mixture. After the reaction, the obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. To the obtained residue was added diethyleth-er, to thereby obtain 40 g of Phe-Gly-OBn para-toluene-sulfonate.
(2) Synthesis of Trt-Gly-Gly Synthesis of Trt-Gly-Gly was conducted in substan-tially the same manner as in step 1 of Example 6. That is, Gly-Gly (manufactured and sold by PEPTIDE INSTITUTE
INC., Japan, 6.6 g, 50 mmol) was dissolved in a mixture of 20 ml of H20, 40 ml of 2-propanol and 15 ml of diethylamine, to thereby obtain a solution. To the ob-tamed solution was portionwise added trityl chloride (18.1 g, 65 mmol), followed by stirring for one hour.
To the resulatant reaction mixture was added H20, to thereby generate a precipitate. The generated pre-cipitate was collected, washed with water and then dissolved into 5 ml of acetic acid, to thereby obtain an acidic solution. The obtained acidic solution was evaporated to dryness, to thereby obtain 13.1 g of Trt-Gly-Gly.
(3) Synthesis of Trt-Gly-Gly-Phe-Gly-OBn To 10 ml of dry DMF were added 1.54 g of Trt-Gly Gly, 0.52 g of N-hydroxysuccinimide and 0.93 g of DCC, followed by effecting a reaction at 4 °C for 3 hours, to thereby obtain a reaction mixture. To the obtained reaction mixture was added a DMF solution containing 2.0 g of Phe-Gly-OHn para-toluenesulfonate synthesized in item (1) and 0.41 g of N-methylmorpholine, which are dissolved in 10 ml of DMF, followed by effecting a reaction at 4 °C for 15 hours, to thereby obtain a reaction mixture. A precipitate contained in the ob-tained reaction mixture was removed and the resultant solution was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9365, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform /
methanol = 20/1), to thereby obtain 1.5 g of Trt-Gly-Gly-Phe-Gly-OBz.
(4) Synthesis of Trt-Gly-Gly-Phe-Gly 1.3 g of Trt-Gly-Gly-Phe-Gly-OBn obtained in item (3) was dissolved in 20 ml of DMF, to thereby obtain a solution. To the obtained solution were added 0.5 g of 10 % palladium-carbon and 0.4 g of 4-cyclohexadiene, followed by effecting a reaction at room temperature for 30 minutes, to thereby obtain a reaction mixture.
The obtained reaction mixture was subjected to filtra-tion to remove the catalyst, to thereby obtain a solu-tion. The obtained solution was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9365, Silica gel 60, 200-400 mesh, manu-factured and sold by E. Merck, Darmstadt, Germany, eluent . chloroform / methanol = 7/1), to thereby obtain 1.0 g of Trt-Gly-Gly-Phe-Gly.
Anal. Calcd for . C34H34N405 C, 70.57 ; H, 5.92 ; N, 9.68 Found: C, 70.03 ; H, 6.07 ; N, 9.67 Analysis of amino acids .
Phe (1) 1.00, Gly (3) 2.91 Conditions of Hydrolysis . 6N HC1, 110 °C, 22 hrs Reference Example 2 (Production of Z-Gly-Gly-Phe) BOC-Phe (manufactured and sold by PEPTIDE INSTI-TUTE INC., Japan, 10.6 g) was dissolved in 100 ml of ethyl acetate, to thereby obtain a solution. To the obtained solution were added 10.0 g of phenacyl bromide and 5.1 g of triethylamine while cooling over ice, followed by stirring. The reaction temperature was elevated to room temperature, followed by stirring overnight to effect a reaction, thereby obtaining a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was dissolved in 50 ml of ethyl acetate and the resultant solution was washed with a saturated aqueous sodium hydrogencarbonate solution and then with saturated saline. The washed solution was dried with magnesium sulfate and concentrated under reduced pressure, to thereby obtain 13.4 g of BOC-Phe phenacyl ester. Further, to 1.9 g of BOC-Phe phenacyl ester was added 5 ml of trifluoroacetic acid (TFA), followed by stirring for 10 minutes. The resultant reaction mixture was evaporated to dryness under re-duced pressure for removing TFA, to thereby obtain a residue. To the obtained residue were added 20 ml of DMF, 0.61 g of N-methylmorpholine, 1.24 g of DCC, 0.81 g of HOBT and BOC-Gly (manufactured and sold by PEPTIDE
INSTITUTE INC., Japan 1.05 g), followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was concentrated under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in 50 ml of ethyl acetate, and the resultant solution was washed with 0.1 N hydrochloride cooled with ice, saturated saline, a saturated aqueous sodium hydrogencarbonate solution and again saturated saline successively. The washed solution was dried with magnesium sulfate and concentrated under reduced pressure, to thereby obtain 1.5 g of BOC-Gly-Phe phenacyl ester. Further, to 1.6 g of BOC-Gly-Phe phenacyl ester was added 5 ml of tri-fluoroacetic acid (TFA), followed by stirring for 10 minutes, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness under reduced pressure for removing TFA, to thereby obtain a residue. To the obtained residue were added 20 ml of DMF, 0.40 g of N-methylmorpholine, 0.83 g of DCC, 0.54 g of HOBT and 0.84 g of Z-Gly (manufactured and sold by Kokusan Chemical Works Ltd., Japan), fol-lowed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reac-tion mixture was concentrated under reduced pressure, to thereby obtain a residue. The obtained residue was dissolved in 50 ml of ethyl acetate and the resultant solution was washed with 0.1 N solution hydrochloride cooled with ice, saturated saline, a saturated aqueous sodium hydrogencarbonate solution and again saturated saline successively. The washed solution was dried with magnesium sulfate and concentrated under reduced pressure, to thereby obtain 1.1 g of Z-Gly-Gly-Phe phepacyl ester. 1.1 g of Z-Gly-Gly-Phe phenacyl ester was dissolved in 30 ml of 90o acetic acid, to obtain a mixture. To the obtained mixture was added 4 g of zinc dust, followed by stirring at room temperature for 5 hours, to thereby obtain a reaction mixture. The obtained reaction mixture was subjected to filtration and evaporated to dryness, to thereby obtain a residue.
The obtained residue was dissolved in 30 ml of ethyl acetate and the resultant solution was washed with 10 citric acid and then with saturated saline successive-ly, dried with magnesium sulfate and concentrated under reduced pressure, to thereby obtain 0.62 g of Z-Gly-Gly-Phe.

Example 9 (Step 1) Production of 2'-Gly-Gly-Phe-Gly-pacli-taxel hydrochloride (32) Trt-Gly-Gly-Phe-Gly (739 mg, 1.3 mmol) obtained in Reference Example 1, dimethylaminopyridine (158 mg, 1.3 mmol) and paclitaxel (manufactured and sold by DABUR, India, 853 mg, 1.0 mmol) were dissolved in 20 ml of methylene chloride, to thereby obtain a solution. To the obtained solution was added N,N'-diisopropylcarbo-diimide (164 mg, 1.3 mmol), followed by stirring at room temperature for 4 hours, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue.
The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 50 cm, eluent .
methylene chloride / methanol / acetonitrile =
95/5/30), to thereby obtain 1,246 mg of 2'-Na-Trt-Gly-Gly-Phe-Gly-paclitaxel.
HRMS: m/z 1414.5763 (M + H)+ . the molecular weight calculated for C81H84018N5 1414.5811 1,100 mg of the above-obtained compound was treat-ed with 10 ml of 75 % acetic acid to effect a reaction for removing N-trityl group. The resultant compound was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 50 cm, eluent . methylene chloride / methanol / acetonitrile = 85/15/5), and subsequently converted to a corresponding hydrochloride thereof, to thereby obtain 530 mg of compound (32).
1H-NMR (DMSO-d6) . 61.00 (s, 3H, Me-17), 1.03 (s, 3H, Me-16), 1.42 (dd, 1H, J = 15.4, 9.2 Hz, H-14b), 1.49 (s, 3H, Me-19), 1.63 (brt, 1H, J = 12.1 Hz, H-6b), 1.74 (dd, 1H, J = 15.4, 9.2 Hz, H-14a), 1.80 (s, 3H, Me-18), 2.11 (s, 3H, Ac-10), 2.23 (s, 3H, Ac-4), 2.30 (m, 1H, H6a), 2.72 (dd, 1H, J = 13.9, 10.2 Hz, PheCH2Hb), 3.02 (dd, 1H, J = 13.9, 3.8 Hz, PheCH2CHa), 3.52 (brs, 2H, GlyCH2), 3.56 (d, 1H, J = 7.2 Hz, H-3), 3.66 (dd, 1H, 16.9, 5.4 Hz, GlyCH2b), 3.84 (dd, 1H, 16.9, 5.4 Hz, GlyCH2a), 4.01 (dd, 2H, J = 14.5, 8.4 Hz, H-20a, H-20b), 4.01 (2H, GlyCH2), 4.09 (m, 1H, H-7), 4.55 (ddd, 1H, J = 10.2, 8.5, 3.8 Hz, PheCH2CH), 4.61 (s~ 1H, OH-1), 4.89 (dd, 1H, J = 8.9, 1.3 Hz, H-5), 4.92 (brs, 1H, OH-7), 5.41 (d, 1H, J = 7.2 Hz, H-2), 5.43 (d, 1H, J = 6.3 Hz, H-2'), 5.51 (t, 1H, J = 8.5 Hz, H-3'), 5.83 (t, 1H, J = 9.2 Hz, H-13), 6.29 (s, 1H, H-10), 7.10-8.00 (aromatic, 20H), 8.33 (d, 1H, PheCONH), 8.51 (t, 1H, J = 5.5 Hz, GIyCONH), 8.69 (t, 1H, J = 6.0 Hz, GIyCONH), 9.34 (d, 1H, J = 8.5 Hz, CONH-3') HRMS: m/z 1172.4711 (M + H)+ . the molecular weight calculated for C62H70018N5 1172.4716 Anal. Calcd for: C62H6g018N5'HC1~2.5 H20 .
C, 59.40 ; H, 6.03 ; N, 5.59.
Found: C, 59.55 ; H, 6.04 ; N, 5.60 (Step 2) Production of carboxymethylated dextran-2'-Gly-Gly-Phe-Gly-paclitaxel (33) 1.0 g of carboxymethylated dextran sodium salt (1) obtained in step 1 of Example 1 was dissolved in 20 ml of water. To the resultant solution was added 20 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture was added 8 ml of a solution contain-ing 200 mg of 2'-Gly-Gly-Phe-Gly-paclitaxel (32) ob-tained in step 1 of Example 9, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and 5 ml of a solution containing 1.0 g of 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-di-methylformamide, followed by stirring at room tempera-ture for 6 hours, to thereby obtain a reaction mixture.
The obtained reaction mixture was poured into 1 liter of ethanol, to thereby generate a precipitate. The generated precipitate was collected and dissolved in 100 ml of purified water. The resultant solution was poured into 1 liter of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 1,050 mg of compound (33) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (33) was calculated from the visible light absorbance at 254 nm, and found to be 3.7 % by weight, based on the weight of compound (33). The gel filtration chro-matogram of compound (33) was obtained using an ultra-violet detector (wavelength: 220 nm), and is shown in Fig. 25. The ultraviolet absorption spectrum of com-pound (33) is shown in Fig. 26.
Example 10 (Step 1) Production of 7-Gly-Gly-Phe-Gly-paclitaxel (34) Paclitaxel (manufactured and sold by DABUR, India, 427 mg, 0.5 mmol) was dissolved in methylene chloride, to thereby obtain a solution. To the obtained solution was added diisopropylethylamine (129 mg, 1.0 mmol), to thereby obtain a mixture. To the obtained mixture was added benzyloxycarbonyl chloride (170 mg, 1.0 mmol) while cooling over ice, followed by stirring overnight at room temperature, to thereby obtain a reaction mixture. The obtained reaction mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatogra-phy (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 2.0 x 30 cm, eluent . methylene chloride / acetonitrile = 80/20), to thereby obtain 423 mg of 2'-Z-paclitaxel.
2'-Z-paclitaxel (270 mg, 0.27 mmol) was dissolved in methylene chloride, to thereby obtain a solution.
To the obtained solution were added Z-gly (85 mg, 0.41 mmol), N,N'-dicyclohexylcarbodiimide (84 mg, 0.41 mmol) and dimethylaminopyridine (50.1 mg, 0.41 mmol), fol-lowed by stirring at room temperature for 3 days, to thereby obtain a reaction mixture. The obtained reac-tion mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No.
2~ 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 50 cm, eluent . methylene chloride / acetonitrile =
80/20), to thereby obtain 300 mg of 2'-Z-7-Z-Gly-pacli-taxel.
2'-Z-7-Z-Gly-paclitaxel (200 mg, 0.16 mmol) was dissolved in 100 ml of ethyl acetate, to thereby obtain a solution. To the obtained solution was added a palladium-carbon catalyst, followed by introducing thereinto hydrogen gas while stirring, to thereby effect a reaction. After completion of the reaction, the resultant reaction mixture was subjected to filtra-tion to remove the catalyst, to thereby obtain a solu-tion. The obtained solution was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manu-factured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 50 cm, eluent . methylene chloride /
acetonitrile = 50/50), to thereby obtain 87 mg of 7-Gly-paclitaxel.
7-Gly-paclitaxel (70 mg, 0.09 mmol) was dissolved in 20 ml of N,N-dimethylformamide, to thereby obtain a solution. To the obtained solution were added the Z-Gly-Gly-Phe (58 mg, 0.13 mmol) obtained in Reference Example 2, water-soluble carbodiimide (26 mg, 0.13 mmol) and 1-hydroxybenzotriazole (18 mg, 0.13 mmol), followed by stirring at room temperature for 3 days, to thereby obtain a reaction mixture. The obtained reac-tion mixture was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No.
9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 50 cm, eluent . methylene chloride / methanol / acetoni-trile = 85/15/5), to thereby obtain 94 mg of 7-Z-Gly-Gly-Phe-Gly-paclitaxel.
7-Z-Gly-Gly-Phe-Gly-paclitaxel (80 mg, 0.06 mmol) was dissolved in 20 ml of methanol, to thereby obtain a solution. To the obtained solution was added a pallad-ium-carbon catalyst, followed by introducing hydrogen gas thereinto while stirring, to thereby effect a reaction. After completion of the reaction, the reac-tion mixture was subjected to filtration to remove the catalyst, to thereby obtain a solution. The obtained solution was evaporated to dryness, to thereby obtain a residue. The obtained residue was purified by silica gel column chromatography (silica gel . Art No. 9385, Silica gel 60, 200-400 mesh, manufactured and sold by E. Merck, Darmstadt, Germany, column . 4.0 x 30 cm, eluent . methylene chloride / methanol / acetonitrile =
95/5/30), to thereby obtain 50 mg of compound (34).
1H-NMR (DMSO-d6) . 80.99 (s, 3H, Me-17), 1.05 (s, 3H, Me-16), 1.67 (s, 3H, Me-19), 1.68 (m, 1H, H6b), 1.75 (s, 3H, Me-18), 1.79 (dd, 1H, J = 15.3, 8.9 Hz, H-14b), 1.90 (dd, 1H, J = 15.3, 8.9 Hz, H-14a), 2.15 (s, 3H, Ac-10), 2.26 (s, 3H, Ac-4), 2.42 (m, 1H, H-6a), 2.74 (dd, 1H, J = 13.9, 10.5 Hz, PheCH2CHb), 3.05 (dd, 1H, J = 13.9, 3.8 Hz, PheCH2CHa), 3.54 (brs, 2H, GlyCH2), 3.66 (dd, 1H, J = 16.8, 5.3 Hz, GlyCH2b), 3.69 (dd, 1H, J = 16.8, 5.3 Hz, GlyCH2a), 3.72 (d, 1H, J =
6.8 Hz, H-3), 3.80 (dd, 1H, J = 16.8, 5.8 Hz, GlyCH2b), 3.85 (dd, 1H, J = 16.8, 5.8 Hz, GlyCH2a), 4.06 (s, 2H, H-20), 4.57 (ddd, 1H, J = 10.5, 8.9, 3.8 Hz, PheCH2CH), 4.62 (brt, 1H, J = 7.0 Hz, H-2'), 4.85 (s, 1H, OH-1), 4.99 (d, 1H, J = 9.8 Hz, H-5), 5.42 (t, 1H, J = 8.1 Hz, H-3'), 5.43 (d, 1H, J = 6.8 Hz, H-2), 5.47 (dd, 2H, J =
10.4, 7.6 Hz, H-7), 5.91 (t, 1H, J = 8.5 Hz, H-13), 6.23 (d, 1H, OH-2'), 7.00-8.00 (aromatic, 20H), 8.05 (brs, 1H, NH2), 8.30 (d, 1H, J = 8.9 Hz, PheCONH), 8.47 (t, 1H, J = 5.6 Hz, GIyCONH), 8.56 (t, 1H, J = 5.5 Hz, GIyCONH), 9.00 (d, 1H, J = 8.5 Hz, CONH-3') (Step 2) Production of carboxymethylated dextran-7-Gly-Gly-Phe-Gly-paclitaxel (35) 1.0 g of carboxymethylated dextran sodium salt (1) obtained in step 1 of Example 1 was dissolved in 20 ml of water. To the resultant solution was added 20 ml of N,N-dimethylformamide while cooling over ice. To the resultant mixture was added 8 ml of a solution contain-ing 180 mg of 7-Gly-Gly-Phe-Gly-paclitaxel (34) ob-tained in step 1 of Example 10, which was dissolved in a mixture of water and N,N-dimethylformamide (1:1), and ml of a solution containing 1.0 g of 1-ethoxycarbo-nyl-2-ethoxy-1,2-dihydroquinoline dissolved in N,N-di-5 methylformamide, followed by stirring at room tempera-ture for 6 hours, to thereby obtain a reaction mixture.
The obtained reaction mixture was poured into 1 liter of ethanol, to thereby generate a precipitate. The generated precipitate was collected and dissolved in 100 ml of purified water. The resultant solution was poured into 1 liter of ethanol, to thereby generate a precipitate. The generated precipitate was collected and washed with acetone and ether successively, to thereby obtain 1,050 mg of compound (35) (drug complex) as a white amorphous substance.
The amount of the drug introduced into compound (35) was calculated from the visible light absorbance at 254 nm, and found to be 7.4 o by weight, based on the weight of compound (35). The gel filtration chro-matogram of compound (35) was obtained using an ultra-violet detector (wavelength: 220 nm), and is shown in Fig. 27. The ultraviolet absorption spectrum of com-pound (35) is shown in Fig. 28.
Experiment 1 Dissolution of compounds (3) and (15) in physiological saline 50 mg of compound (3) obtained in Example 1 was successfully dissolved completely in 0.5 ml of physio-logical saline. This means that 37 mg of paclitaxel dissolved in 10 ml of physiological saline, i.e., the dissolution ratio of compound (3) in terms of paclitax-el was 3.7 mg/ml (physiological saline).
50 mg of compound (15) obtained in Example 4 was successfully dissolved completely in 0.5 ml of physio-logical saline. This means that 16 mg of paclitaxel was dissolved in 10 ml of physiological saline, i.e.
the dissolution ratio of compound (15) in terms of paclitaxel was 1.6 mg/ml (physiological saline).
On the other hand, 1 mg of paclitaxel (manufac-tured and sold by DABUR, India) could not be dissolved completely in 10 ml of physiological saline.
Experiment 2 Evaluation of the release of paclitax-el from compounds (3), (7), (11) and (15) in mouse serum and human serum Each of compounds (3), (7), (11) and (15) (drug complexes) respectively obtained in Examples l, 2, 3 and 4 was individually dissolved in physiological saline so that the concentration thereof in terms of paclitaxel was 125 ug/ml, to thereby obtain four solu-tions. 20 ul of each of the above-obtained four solu-tions was individually added to each of 200 ul of mouse serum and 200 ul of human serum, and the amounts of paclitaxel released from the respective compounds at 37 °C were determined as follows.
The recovery of paclitaxel from the serum by solid-phase extraction and subsequent determination of the amount of paclitaxel released from each of com-pounds (3), (7), (11) and (15) in serum by HPLC were conducted according to the method described in Yakugaku Zasshi, 114, P.351-355 (1994). The changes (with the lapse of time) of the release of paclitaxel from the compounds in mouse serum and human serum are shown in Figs. 29 and 30, respectively.
With respect to the rates of the release of pacli-taxel from the compounds, the same tendency was ob served in both of mouse serum and human serum. The magnitudes of the rates of the release of paclitaxel from the respective compounds were in the order of (3) > (7) > (11) > (15). The rate of the release of pacli-taxel has a correlation with the magnitude of the steric hindrance of the amino acid used as a spacer in the compound (drug complex).
Experiment 3 Antitumor assays (1) Test sample solutions were prepared by separately dissolving, into physiological saline, compounds (3), (7) and (15) respectively obtained in Examples 1, 2 and 3. Further, a control solution was prepared by dis-solving paclitaxel per se into a mixture of ethanol, Cremophore EL (manufactured and sold by Sigma, U.S.A.) and physiological saline. Thus, four types of solu-tions, namely, three different types of test sample solutions and one control solution were obtained.
Twenty-eight female C57BL/6 mice (six weeks old) were divided into four groups, each consisting of seven mice, and subsequently, B16 melanoma cells were intra-dermally transplanted to the groin of each of the mice (5 x 106 cells per mouse). After eight days from the transplantation, the above-mentioned four types of solutions were administered to the transplanted mice at the tails thereof intravenously so that the mice be-longing to the same group received the administration of the same type of solution. The amounts of the test sample solutions, administered to the mice of the different groups are all the same, and each of the doses of compounds (3), (7) and (15) was 50 mg/kg in terms of paclitaxel. With respect to the control solution, the dose of paclitaxel was 50 mg/kg.
Separately, a group consisting of thirteen mice, which were transplanted with B16 melanoma cells in the same manner as mentioned above, was provided. Each of the mice of such group received the administration of physiological saline, to thereby obtain a non-treated group of mice.
After six days from the administration of the test sample solution, the control solution and the physio-logical saline to the mice, evaluation was made of the antitumor activity of each compound in terms of the relative average tumor volume (%), namely, the ratio of the average tumor volume of the mice of each of the four treated groups (the mice of the treated groups had received the administration of the three types of test sample solutions and the control solution, respective-lY), relative to the average tumor volume of the mice of the non-treated group (the mice of the non-treated group had received the administration of physiological saline).
The tumor volume was determined as follows. The external major and minor diameters (a and b, respec-tively) (each in mm) of the tumor were measured, and the tumor volume (V) was obtained according to the following formula.

a x b2 V = (mm)3 The relationship between the doses of compounds (3), (7) and (15) and the relative average tumor volumes (o) is shown in Fig. 31.
The antitumor activity of compound (3) of the present invention, observed with respect to the group of mice which had received the administration of 50 mg/kg (in terms of paclitaxel) of compound (3), was significantly excellent, as compared to the antitumor activity of paclitaxel, observed with respect to the group of mice which had received the administration of paclitaxel er se.
The antitumor activity of compound (7) of the present invention, observed with respect to the group of mice which had received the administration of 50 mg/kg (in terms of paclitaxel) of compound (7), was also excellent, as compared to the antitumor activity of paclitaxel, observed with respect to the group of mice which had received the administration of paclitax-el per se.
The antitumor activity of compound (15), observed with respect to the group of mice which had received the administration of 50 mg/kg (in terms of paclitaxel) of compound (15), was relatively weak, as compared to the antitumor activity of paclitaxel, observed with respect to the group of mice which had received the administration of paclitaxel per se.
The magnitudes of the antitumor activities of the respective compounds were in the order of (3) > (7) >
(15). The antitumor activity has a correlation with the rate of the release of the drug, which is described in Example 2.
Experiment 4 Evaluation of the release of paclitax-el from compounds (3), (19), (21) and (23) in mouse serum and human serum Each of compounds (3), (19), (21) and (23) (drug complexes) respectively obtained in Examples 1, 5, 6, and 7 was individually dissolved in physiological saline so that the concentration thereof in terms of paclitaxel was 125 ug/ml, to thereby obtain four solu-tions. 20 ug of each of the above-obtained four solu-tions was individually added to each of 200 ul of mouse serum and human serum, and the amounts of paclitaxel released from the respective compounds at 37 °C were determined as follows.
The recovery of paclitaxel from the serum by solid-phase extraction and subsequent determination of the amount of paclitaxel released from each of com-pounds (3), (19), (21) and (23) in serum by HPLC were conducted according to the method described in Yakugaku Zasshi, 114, P.351-355 (1994). The changes (with the lapse of time) of the release of paclitaxel in mouse serum and human serum are shown in Figs. 32 and 33, respectively.
With respect to the rates of the release of pacli-taxel from compounds (3) and (19) in mouse serum, the magnitudes of the rates of the release from the respec-five compounds were in the order of (3) > (19). The rate of the release of paclitaxel has a correlation with the magnitude of the steric hindrance of the amino acid used as a spacer in the compound (drug complex).
Further, with respect to the rates of the release of paclitaxel from compounds (21) and (23) in both of mouse serum and human serum, the magnitudes of the rate of the release of paclitaxel from the respective com-pounds were in the order of (21) > (23). The rate of the release of paclitaxel has a correlation with the magnitude of the steric hindrance of the amino acid di-rectly bonded to the drug, wherein the amino acid is contained in the peptide used as a spacer in the com-pound (drug complex).

Experiment 5 Dissolution of compounds (5) and (17) in physiological saline 25 mg of compound (5) obtained in Example 1 was successfully dissolved completely in 1 ml of a physio-logical saline. This means that 36 mg of paclitaxel dissolved in 10 ml of physiological saline, i.e., the dissolution ratio of compound (5) in terms of paclitax-el was 3.6 mg/ml (physiological saline).
20 mg of compound (17) obtained in Example 4 was successfully dissolved completely in 1 ml of physiolog-ical saline. This means that 28 mg of paclitaxel was dissolved in 10 ml of physiological saline, i.e., the dissolution ratio of compound (17) in terms of pacli-taxel was 2.8 mg/ml (physiological saline).
On the other hand, 1 mg of paclitaxel (manufac-tured and sold by DABUR, India) could not be dissolved completely in 10 ml of physiological saline.
Experiment 6 Evaluation of the release of paclitax-el from compounds (5), (9), (13) and (17) in mouse serum and human serum Each of compounds (5), (9), (13) and (17) (drug complexes) respectively obtained in Examples 1, 2, 3 and 4 was individually dissolved in physiological saline so that the concentration thereof in terms of paclitaxel was 250 ug/ml, to thereby obtain four solu-tions. 20 ul of each of the above-obtained four solu-tions was individually added to each of 200 ul of mouse serum and human serum, and the amounts of paclitaxel released from the respective compounds at 37 °C were determined as follows.
The recovery of paclitaxel from the serum by solid-phase extraction and subsequent determination of the amount of paclitaxel released from each of com-pounds (5), (9), (13) and (17) in serum by HPLC were conducted according to the method described in Yakugaku Zasshi, 114, P.351-355 (1994). The changes (with the lapse of time) of the release of paclitaxel from the compounds in mouse serum and human serum are shown in Figs. 34 and 35, respectively.
With respect to the rates of the release of pacli-taxel from the compounds, the same tendency was ob-served in both of mouse serum and human serum. The magnitudes of the rates of the release of paclitaxel from the respective compounds were in the order of (5) > (9) > (13) > (17). The rate of the release of pacli-taxel has a correlation with the magnitude of the steric hindrance of the amino acid used as a spacer in the compound (drug complex).

Experiment 7 Evaluation of the release of dexam-ethasone from compounds (24), (26), (28) and (30) in mouse serum and human serum Each of compounds (24), (26), (28) and (30) (drug complexes) obtained in Example 8 was dissolved in physiological saline so that the concentration thereof in terms of dexamethasone was 80 ug/ml, to thereby obtain four solutions. 50 ul of each of the above-obtained four solutions was individually added to each of 250 ul of mouse serum and 250 ul of human serum, and the amounts of dexamethasone released from the respec-tive compounds at 37 °C were determined as follows.
The recovery and quantitative analysis of dexam-ethasone in serum were conducted as follows: 250 ul of phosphate buffer (pH 7.4) was added to 250 ml of each of the sera to which the above-mentioned solution was added, to thereby obtain a mixture. To the obtained mixture was added 3 ml of a solution of hydrocorrisone acetate (as an internal standard for the below-men-tinned HPLC analysis, the concentration of hydrocorti-Bone acetate: 10 ng/ml) in a mixture of acetonitrile and methanol (acetonitrile / methanol = 4/1) and sub-jected to centrifugation (3,000 rpm, 10 minutes, 4 °C).
To 700 ul of the resultant supernatant was added 700 ul of distilled water, to thereby obtain a mixture. The obtained mixture was subjected to filtration with a membrane filter (pore size 0.2 um), and the resultant filtrate was used as a sample for the quantitative analysis of dexamethasone by HPLC under the following conditions.
The conditions for HPLC
Column . Asahipak HIKARISIL C18 (4.6 x 150 mm) Flow rate . 1.0 ml/min.
Column temperature . room temperature The detected wavelength . 254 nm Mobile phase . Linear gradient 0 min. . 20 % aqueous acetonitrile (20 % CH3CN / H20) 20 min. . 50 % aqueous acetonitrile (50 % CH3CN / H20) With respect to the rates of the release of dexam-ethasone from the compounds, the same tendency was observed in both of mouse serum and human serum. The magnitudes of the rates of the release of dexamethasone from the respective compounds were in the order of (30) > (26) > (28) > (24). The rate of the release of dexamethasone has a correlation with the magnitude of the steric hindrance of the amino acid used as a spacer in the compound (drug complex). Illustratively stated, 98 % or more of dexamethasone introduced into compound (30) was released from compound (30) very quickly, whereas approximately 95 % of dexamethasone introduced into compound (26) was released from compound (26), approximately 70 % of dexamethasone introduced into compound (28) was released from compound (28), and only % or less of dexamethasone introduced into compound (24) was released from compound (24).
10 Experiment 8 Dissolution of compounds (33) and (35) in physiological saline 1 g of compound (33) obtained in Example 9 was successfully dissolved completely in 10 ml of a physio-logical saline. This means that 37 mg of paclitaxel dissolved in 10 ml of physiological saline, i.e. the dissolution ratio compound (33) in terms of paclitaxel was 3.7 mg/ml (physiological saline).
1 g of compound (35) obtained in Example 10 was successfully dissolved completely in 10 ml of physio-logical saline. This means that 74 mg of paclitaxel was dissolved in 10 ml of physiological saline, i.e.
the dissolution ratio of compound (35) in terms of paclitaxel was 7.4 mg/ml (physiological saline).
On the other hand, 1 mg of paclitaxel (manufac-tured and sold by DABUR, India) could not be dissolved completely in 10 ml of physiological saline.
Experiment 9 Evaluation of the release of paclitax-el from compounds (33) and (35) in serum of B-16 mela-noma-transplanted mouse Each of compounds (33) and (35) (drug complexes) respectively obtained in Examples 9 and 10 was indi-vidually dissolved in physiological saline so that the concentration thereof in terms of paclitaxel was 250 ug/ml, to thereby obtain two solutions. 20 ul of each of the above-obtained two solutions was added to 200 ul of serum of B-16 melanoma-transplanted mouse, and the amounts of paclitaxel released from the respective compounds at 37 °C were determined as follows.
The recovery of paclitaxel from the serum by solid-phase extraction and subsequent determination of the amount of paclitaxel released from each of com-pounds (33) and (35) in serum by HPLC were conducted according to the method described in Yakugaku Zasshi, 114, P.351-355 (1994). The changes (with the lapse of time) of the release of paclitaxel from the compounds in mouse serum and human serum are shown in Fig. 36.
In mouse serum, the concentration of paclitaxel released from compound (33) became maximum at a point in time between 8 and 24 hours after the addition of compound (33) to serum. The release of paclitaxel from compound (35) was slow, as compared to that from com-pound (33).
Experiment 10 Antitumor assays (2) A test sample solution was prepared by dissolving compound (33) obtained in Example 9 into physiological saline. Further, a control solution was prepared by dissolving paclitaxel per se into a mixture of ethanol, Cremophore EL (manufactured and sold by Sigma, U.S.A.) and physiological saline. Thus, two types of solu-tions, namely, one sample solution and one control solution were obtained.
Twenty-one female C57BL/6 mice (six weeks old) were divided into three groups, each consisting of seven mice, and subsequently, B16 melanoma cells were intradermally transplanted to the groin of each of the mice (5 x 106 cells per mouse). After eight days from the transplantation, the above-mentioned two types of solutions were administered to the transplanted mice at the tails thereof intravenously so that the mice be-longing to the same group received the administration of the same type of solution. The amount of the test sample solution was varied depending on the group of mice. That is, two different doses of compound (33), 20 mg/kg and 50 mg/kg, in terms of paclitaxel, were administered so that the mice belonging to the same group received the administration of the same dose of compound (33). With respect to the control solution, the dose of paclitaxel was 50 mg/kg.
Separately, a group consisting of thirteen mice, which were transplanted with H16 melanoma cells in the same manner as mentioned above, was provided. Each of the mice of such group received the administration of physiological saline, to thereby obtain a non-treated group of mice.
After six days from the administration of the test sample solution, the control solution and the physio-logical saline to the mice, evaluation was made of the antitumor activity of the compound in terms of the relative average tumor volume ($), namely, the ratio of the average tumor volume of the mice of each of the three treated groups (the mice of the treated groups received the administrations of the test sample solu-tion and the control solution, respectively), relative to the average tumor volume of the mice of the non-treated group (the mice of the non-treated group had received the administration of physiological saline).
The tumor volume was determined as follows. The external major and minor diameters (a and b, respec-tively) (each in mm) of the tumor were measured and the tumor volume was obtained according to the following formula.
a x b2 V = (mm)3 The relationship between the doses of compound (33) and the relative average tumor volume (o) is shown in Fig. 37.
The antitumor activity of compound (33), observed with respect to the group of mice which had received the administration of 50 mg/kg (in terms of paclitaxel) of compound (33), was significantly excellent, as compared to the antitumor activity of paclitaxel, observed with respect to the group of mice which had received the administration of paclitaxel per se.
Experiment 11 Antitumor assays (3) A test sample solution was prepared by dissolving compound (33) obtained in Example 9 into physiological saline. Further, a control solution was prepared by dissolving paclitaxel per se into a mixture of ethanol, Cremophore EL (manufactured and sold by Sigma, U.S.A.) and physiological saline. Thus, two types of solutions, namely, one type of test sample solution and one control solution were obtained.
Six female Balb/C mice (six weeks old) were divid-ed into two groups, each consisting of three mice, and subsequently, a 4 o suspension of colon 26 tumor cells was intradermally transplanted to the flank of each of the mice. After two days from the transplantation, each of the above-mentioned two types of solutions was individually administered to each of the transplanted mice at the tails thereof intravenously. That is, one group of mice received the administration of the test sample solution, and another group of mice received administration of the control solution. With respect to the test sample solution, the dose of compound (33) was to 50 mg/kg in terms of paclitaxel. With respect to the control solution, the dose of paclitaxel was 50 mg/kg. And every 4 days after the above administra-tion, substantially the same administration was repeat-ed several times.
Separately, a group consisting of five mice, which were transplanted with Colon 26 tumor cells in the same manner as mentioned above, was provided. Each of the mice of such group received the administration of only physiological saline in the same manner as in the case of the administration of the test sample solution, to thereby obtain a non-treated group of mice.
Evaluation was made of the antitumor activity in terms of the change (with the lapse of time) of the average tumor volume (%).
The tumor volume was determined as follows. The external major and minor diameters (a and b, respec-tively) (each in mm) of the tumor were measured, and the tumor volume was obtained according to the follow-ing formula.
a x b2 V = (mm)3 The changes (with the lapse of time) in average tumor volume of the mice which had received the admin-istrations with respect to each of the test sample solution, the control solution and the physiological saline are shown in Fig. 38.
As is apparent from Fig. 38, the antitumor activi-ty of compound (33), observed with respect to the group of mice which had received the administrations of 50 mg/kg (in terms of paclitaxel) of compound (3), was significantly excellent, as compared to the antitumor activity of paclitaxel, observed with respect to the group of mice which had received the administration of INDUSTRIAL APPLICABILITY
The drug complex of the present invention is capable of not only surely controlling the rate of the release of a drug therefrom, but also enhancing the transferability of the drug to target tissues and the pharmacological effect of the drug. Therefore, the drug complex of the present invention is extremely valuable in the field of medicine.
For example, when drug complex of the present invention has a structure in which the drug is a taxane compound, the spacer is an amino acid and the carrier is a carboxyalkyldextran, the drug complex is capable of not only surely controlling the rate of release of the taxane compound therefrom, but also exhibiting various advantageous effects, such as an improved solubility in physiological saline, as compared to that of taxane compounds per se. Thus, it becomes possible to administer a taxane compound intravenously without using an adjuvant for dissolving the taxane compound.

Claims (20)

Claims
1. A drug complex of a drug having a hydroxyl group, which is capable of controlling the rate of the release of the drug therefrom in blood, said drug complex comprising:
(A) at least one carrier selected from the group consisting of saccharides each having at least one carboxyl group, polyethylene glycols each having at least one carboxyl group, straight or branched C2-C8 aliphatic carboxylic acids each having at least one carboxyl group, and derivatives thereof each having at least one carboxyl group;
(B) at least one spacer comprised of a compound having at least one amino group and at least one car-boxyl group; and (C) at least one drug having a hydroxyl group, wherein said at least one drug (C) is bonded to said at least one spacer (B) through an ester bond formed between the hydroxyl group of said drug (C) and the carboxyl group of said spacer (H) to form at least one drug-spacer block, and wherein said at least one drug-spacer block is bonded to said at least one carrier (A) through an amide bond formed between the amino group of said spacer (B) of said at least one drug-spacer block and the carboxyl group of said at least one carrier (A).
2. The drug complex according to claim 1, wherein the hydroxyl group of said at least one drug (C), which is bonded to the carboxyl group of said at least one spacer (B) to form the ester bond, is a primary hydrox-yl group, and said at least one spacer (B) has a sub-stituent X at the .alpha.-position relative to said carboxyl group of said at least one spacer (B), wherein said substituent X has a steric hindrance parameter (Es) value of from -1.0 to -2.5, said Es value being defined by the following formula (1):
Es = log (k X/k H) (1) wherein k X is the reaction rate constant for the acid hydrolysis reaction of an .alpha.-monosub-stituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COOR x + H2O .fwdarw. X-CH2COOH + R x OH

wherein X is as defined above and R x is a group selected from the group consisting of C1-C18 alkyl groups and C6-C18 aryl groups;
and k H is the reaction rate constant for the acid hydrolysis reaction of an unsubstituted acetic acid ester corresponding to said .alpha.-monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
CH3COOR y + H2O .fwdarw. CH3COOH + R y OH
wherein R y has the same meaning as defined for R x.
3. The drug complex according to claim 1, wherein the hydroxyl group of said at least one drug (C), which is bonded to the carboxyl group of said at least one spacer (B) to form the ester bond, is a secondary hy-droxyl group, and said at least one spacer (B) has a substituent X at the .alpha.-position relative to said car-boxyl group of said at least one spacer (B), wherein said substituent X has a steric hindrance parameter (Es) value of from -0.0 to -2.5, said Es value being defined by the following formula (1):
Es = log (k X/k H) (1) wherein k X is the reaction rate constant for the acid hydrolysis reaction of an .alpha.-monosub-stituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COOR x + H2O .fwdarw. X-CH2COOH + R x OH
wherein X is as defined above and R x is a group selected from the group consisting of C1-C18 alkyl groups and C6-C18 aryl groups;
and k H is the reaction rate constant for the acid hydrolysis reaction of an unsubstituted acetic acid ester corresponding to said .alpha.-monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
CH3COOR y + H2O .fwdarw. CH3COOH + R y OH

wherein R y has the same meaning as defined for R x.
4. The drug complex according to claim 1, wherein said carrier (A) is selected from the group consisting of polysaccharides each having at least one carboxyl group and derivatives thereof each having at least one carboxyl group.
5. The drug complex according to claim 4, wherein said carrier (A) is a carboxyalkyldextran.
6. The drug complex according to claim 4, wherein said carrier (A) is a carboxymethyldextran.
7. The drug complex according to claim 1, wherein said at least one carrier (A) is selected from the group consisting of monosaccarides each having at least one carboxyl group and derivatives thereof each having at least one carboxyl group.
8. The drug complex accorging to claim 1, wherein said at least one spacer (B) is selected from the group consisting of glycine, alanine, leucine, isoleucine and phenylalanine.
9. The drug complex according to claim 1, wherein said at least one spacer (B) is selected from the group consisting of glycylglycylphenylalanylglycine, phenylalanylglycine and glycylphenylalanine.
10. The drug complex according to any one of claims 1, 3, 4, 5, 6, 7, 8 and 9, wherein said at least one drug (C) is se-lected from the group consisting of taxane compounds.
11. The drug complex according to any one of claims 1, 3, 4, 5, 6, 7, 8, 9 and 10, wherein said at least one drug (C) is at least one paclitaxel.
12. The drug complex according to any one of claims 1, 2, 4, 5, 6, 7, 8 and 9, wherein said at least one drug (C) is se-lected from the group consisting of steroids.
13. A medicine comprising the drug complex of any one of claims 1 to 12 in combination with a pharmaceutically accept-able diluent or exipient.
14. The drug complex according to claim 1, wherein:
said drug (C) is at least one taxane compound represented by the following formula (2):

wherein R1 represents a group selected from the group consisting of a straight or branched C1-C6 alkyl group, a straight or branched C2-C6 alkenyl group, a straight or branched C2-C6 alkynyl group, a straight or branched C1-C6 alkoxy group and an unsubstituted or substituted phenyl group; R2 represents a group selected from the group con-sisting of a hydrogen atom, a hydroxyl group and an acetyloxy group; one of R3 and R4 represents a hydrogen atom and the other represents a hydroxyl group, or R3 and R4 together form an oxo group;
one of R5 and R6 represents a hydrogen atom and the other represents a hydroxyl group; Ac repre-sents an acetyl group; and Ph represents a phenyl group, said at least one taxane compound of formula (2) is bonded, at the 2'- or 7-positioned hydroxyl group thereof, to said at least one spacer (B) at the carboxyl group thereof through the ester bond formed between said hydroxyl group and said carboxyl group, said carrier (A) is a carboxyalkyldextran represented by the following formula (3):
wherein each of R7, R8 and R9 independently repre-sents a hydrogen atom or a carboxylalkyl group selected from the group consisting of -(CH2)m-COOH, -CH(CH3)-COOH, -CH2CH(CH3)-COOH and -CH(CH3)CH2-COOH, wherein m represents an integer of from 1 to 4; and n represents an integer of from 50 to 1000, with the proviso that the ratio of the number of carboxylalkyl groups to the number of n is 0.1 to 2.0, and said carboxyalkyldextran is bonded, at the carboxyl moiety of at least one of the carboxyalkyl groups thereof, to said at least one spacer (B) at the amino group thereof through the amide bond formed between said amino group and said carboxyl group.
15. The drug complex according to claim 14, wherein said at least one spacer (B) has a substituent X at the .alpha.-position relative to said carboxyl group, wherein said substituent X
has a steric hindrance parameter (Es) value of from -0.0 to -2.5, said Es value being defined by the following formula (1):
Es = log (k X/k H) (1) wherein k X is the reaction rate constant for the acid hydrolysis reaction of an .alpha.-monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
X-CH2COOR x + H2O .fwdarw. X-CH2COOH + R x OH
wherein X is as defined above and R x is a group selected from the group consisting of C1-C18 alkyl groups and C6-C18 aryl groups; and k H is the reaction rate constant for the acid hydro-lysis reaction of an unsubstituted acetic acid ester corresponding to said .alpha.-monosubstituted acetic acid ester, wherein the acid hydrolysis reaction is represented by the following formula:
CH3COOR y + H2O .fwdarw. CH3COOH + R y OH
wherein R y has the same meaning as defined for R x.
16. The drug complex according to claim 14 or 15, wherein said drug (C) is at least one paclitaxel.
17. The drug complex according to claim 14 or 15, wherein said drug (C) is at least one docetaxel.
18. The drug complex according to claim 14, wherein:
said at least one taxane compound is at least one pacli-taxel, said at least one spacer (B) is at least one glycylgly-cylphenylalanylglycine, said at least one paclitaxel is bonded, at the 2'-positioned hydroxyl group thereof, to said at least one gly-cylglycylphenylalanylglycine at the carboxyl group thereof through the ester bond formed between said hydroxyl group and said carboxyl group, said carrier (A) is a carboxymethyldextran, the molecular weight of said carboxymethyldextran is approximately 150,000 as measured by gel filtration chromatog-raphy using 0.1 M NaCl as an eluate, pullulan as a standard and a chromatograph including a column for gel filtration, said gel filtration chromatography being conducted under conditions wherein the column is TSKgel G4000PW XL (trade name) (manufactured and sold by Tosoh Corporation, Japan), the flow rate of the eluate is 0.8 ml/min. and the temperature of the column is 40 °C and wherein approximately 50 µg of said car-boxymethyldextran is injected to said chromatograph, and the amount of said paclitaxel introduced into said car-boxymethyldextran is from 1 to 10 % by weight, based on the weight of said drug complex.
19. The drug complex according to claim 18, wherein the ratio of the number of carboxyalkyl groups to the number of n is 0.6.
20. An antitumor medicine, which comprises the drug complex of any one of claims 14 to 19 in combination with a pharma-ceutically acceptable diluent or exipient.
CA002251742A 1996-04-15 1997-04-15 Drug complex Expired - Fee Related CA2251742C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11525796 1996-04-15
JP8-115257 1996-04-15
JP32588096 1996-11-22
JP8-325880 1996-11-22
PCT/JP1997/001303 WO1997038727A1 (en) 1996-04-15 1997-04-15 Medicament composite

Publications (2)

Publication Number Publication Date
CA2251742A1 CA2251742A1 (en) 1997-10-23
CA2251742C true CA2251742C (en) 2001-12-11

Family

ID=26453799

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251742A Expired - Fee Related CA2251742C (en) 1996-04-15 1997-04-15 Drug complex

Country Status (7)

Country Link
US (1) US6458347B1 (en)
EP (1) EP0895784B1 (en)
JP (2) JP4420472B2 (en)
AT (1) ATE310538T1 (en)
CA (1) CA2251742C (en)
DE (1) DE69734709D1 (en)
WO (1) WO1997038727A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
CN101816794A (en) * 2001-06-25 2010-09-01 味之素株式会社 Antitumor agent
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10324710A1 (en) 2003-05-30 2004-12-16 Supramol Parenteral Colloids Gmbh Starch derivative Complex
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7282590B2 (en) * 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
RU2375384C2 (en) 2004-09-22 2009-12-10 Ниппон Каяку Кабусики Кайся New block copolymer, micellar preparation and anticarcinogenic agent containing micellar preparation as active component
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
US8940332B2 (en) 2006-05-18 2015-01-27 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
JP5548364B2 (en) * 2006-10-03 2014-07-16 日本化薬株式会社 Polymer conjugates of resorcinol derivatives
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
US8188222B2 (en) 2006-11-08 2012-05-29 Nippon Kayaku Kabushiki Kaisha High molecular weight derivative of nucleic acid antimetabolite
USRE46190E1 (en) 2007-09-28 2016-11-01 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
EP2258397B1 (en) 2008-03-18 2017-10-11 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of physiologically active substance
WO2009136572A1 (en) 2008-05-08 2009-11-12 日本化薬株式会社 Polymer conjugate of folic acid or folic acid derivative
CN102421827B (en) 2009-05-15 2014-07-30 日本化药株式会社 Polymer conjugate of bioactive substance having hydroxy group
WO2012067138A1 (en) 2010-11-17 2012-05-24 日本化薬株式会社 Novel polymer derivative of cytidine metabolism antagonist
WO2013035641A1 (en) 2011-09-11 2013-03-14 日本化薬株式会社 Method for manufacturing block copolymer
JP6453214B2 (en) * 2013-07-10 2019-01-16 生化学工業株式会社 Glycosaminoglycan derivative and method for producing the same
US10675354B2 (en) 2013-07-10 2020-06-09 Seikagaku Corporation Glycosaminoglycan derivative and method for producing same
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6067503A (en) * 1983-09-24 1985-04-17 Kyowa Hakko Kogyo Co Ltd Compound binding mitomycin with polysaccharide
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
DE4236237A1 (en) 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, their preparation and use as medicines
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
WO1994019376A1 (en) * 1993-02-26 1994-09-01 Drug Delivery System Institute, Ltd. Polysaccharide derivative and drug carrier
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU8052194A (en) 1993-10-20 1995-05-08 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5760072A (en) * 1995-12-29 1998-06-02 Pharmachemie B.V. Paclitaxel prodrugs, method for preparation as well as their use in selective chemotherapy
ATE314843T1 (en) * 1996-03-12 2006-02-15 Pg Txl Co Lp WATER SOLUBLE PACLITAXEL PRODRUGS
WO1997038727A1 (en) * 1996-04-15 1997-10-23 Asahi Kasei Kogyo Kabushiki Kaisha Medicament composite

Also Published As

Publication number Publication date
EP0895784A1 (en) 1999-02-10
WO1997038727A1 (en) 1997-10-23
CA2251742A1 (en) 1997-10-23
JP2009287036A (en) 2009-12-10
EP0895784A4 (en) 2003-03-19
ATE310538T1 (en) 2005-12-15
EP0895784B1 (en) 2005-11-23
US6458347B1 (en) 2002-10-01
JP4420472B2 (en) 2010-02-24
DE69734709D1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
CA2251742C (en) Drug complex
CA2134348C (en) Polysaccharide derivatives and drug carriers
RU2130462C1 (en) Polymeric conjugate, a method of its synthesis and a pharmaceutical composition
CA2374964C (en) Process for producing an injectable medicament preparation
US6838450B2 (en) Drug complex
JP4416184B2 (en) Long-acting drugs and pharmaceutical compositions containing them
US6620916B1 (en) Modified physiologically active proteins and medicinal compositions containing the same
AU698944B2 (en) Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations
US8957016B2 (en) Tumor activated prodrugs
AU715632B2 (en) Conjugates useful in the treatment of prostate cancer
US6391305B1 (en) Conjugates useful in the treatment of prostate cancer
AU726434B2 (en) Conjugates useful in the treatment of prostate cancer
JP2020037701A (en) Glycopolysialylation of non-blood coagulation protein
EP1118336A2 (en) Somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP2926829B1 (en) Sugar chain-attached linker, compound containing sugar chain-attached linker and physiologically active substance or salt thereof, and method for producing same
US20030195152A1 (en) Polymeric conjugates of antitumor agents
JPH1192405A (en) Medicinal complex
JP5105166B2 (en) Method for producing polyether
EP2982686A1 (en) Polypeptide having sialylated sugar chains attached thereto
US8642555B2 (en) Prodrugs
WO2018058086A1 (en) Synthetic lipopeptide vaccines and immunotherapeutics
JP5189243B2 (en) Drug complex and carrier for drug delivery
CN114989259A (en) Small molecular peptide Ped4 and application thereof
JP2003034653A (en) Optimized dds compound

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170418